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SUMMARY
During myocardial ischemia the activation of histamine Ha-receptors (H3R) 
results in attenuation of norepinephrine (NE) release from sympathetic nerve 
endings. This action is cardioprotective because excessive NE release from 
sympathetic nerves causes cardiac dysfunction including arrhythmias and sudden 
cardiac death. The antiexocytotic effect of H3R is associated with decreased 
intraneuronal Ca^  ^([Ca^ ]^i). A better understanding of the signaling involved in the 
cardioprotective effect of H3R may offer new therapeutic approaches to 
cardiovascular diseases characterized by hyper-adrenergic activity. This work is 
the first to demonstrate that H3R activation leads to a direct Gpy-induced inhibition 
of voltage-operated calcium channels (VOGG). This action reduces Ga^  ^influx and 
[Ga^^i, thus playing a pivotal role in the H3R-mediated antiexocytotic effects.
Additionally, these studies investigated the interactions between sensory 
nerves, mast cells and sympathetic nerves in the heart. This work established that 
in ischemia/reperfusion the neuropeptides GGRP and Substance P are released 
from sensory G-fibers. Once released, these peptides degranulate adjacent mast 
cells, releasing renin and activating a local cardiac renin-angiotensin system 
(RAS). Angiotensin (ANG) II generated by this local cardiac RAS causes severe 
arrhythmias, in part directly and in part by promoting the release of NE from 
sympathetic nerves via activation of angiotensin type 1-receptors (ATi-receptors). 
This work is the first to demonstrate a pathophysiological link between sensory G- 
fibers and cardiac mast cells in ischemia/reperfusion, resulting in the activation of a 
local cardiac RAS and the promotion of NE release from sympathetic nerve
endings. Unveiling this link highlights an added complexity to nerve/mast cell 
interactions in myocardial ischemia. Since the activation of a local cardiac RAS 
and the consequent excessive release in NE result in detrimental cardiovascular 
effects, these findings may prove significant in the development of new and 
effective therapeutic strategies in conditions such as myocardial ischemia and 
congestive heart failure.
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1. GENERAL INTRODUCTION
1.1 Ischemia: At the Heart of the Problem
The coronary arteries provide the myocardium with a rich supply of oxygen 
in order to maintain its effective function. A myocardial infarction (heart attack) 
occurs when the blood supply to the heart muscle is significantly impaired or 
completely cut off. Such an event may occur because the lining of coronary 
arteries becomes narrow and less flexible due to the buildup of fat, cholesterol and 
other substances which form plaques in a process known as atherosclerosis. 
When one of these plaques breaks up, a blood clot forms at the site of the ruptured 
plaque and this clot can prevent the flow of blood to the myocardium (Boyle, 
2005;Kovanen et al., 2005). A less frequent but equally serious reduction of blood 
flow to the myocardium may occur as the result of coronary artery spasm.
Ischemia is a condition whereby a tissue or organ is starved of oxygen and 
essential nutrients. In myocardial infarction, part of the myocardium becomes 
damaged or dies as a result of myocardial ischemia. A significant problem with 
atherosclerosis and its role in cardiovascular disease is that there may often be no 
associated symptoms. The lack of any apparent warning signs may arise due to 
widening of blood vessels in close proximity to the narrowed arteries, which also 
supply blood to the heart and therefore alleviate ischemia associated with 
atherosclerosis. This network of blood vessels is referred to as the collateral 
circulation and its development is often crucial to the recovery of the myocardium 
following infarction (Fujita, 1995;Frank et al., 1996). The damage incurred by the 
heart as a result of myocardial infarction is dependent on the size of the area
supplied by the blocked artery and the time between ischemic injury and 
treatment. During the infarction, the remaining healthy tissue continues to function 
but is often weakened and less effective (Gomez et al., 2001). If left untreated, this 
can lead to heart failure in which the weakened heart is unable to provide sufficient 
blood to meet the body’s demands. Sudden cardiac death may occur as a direct 
consequence of myocardial ischemia which can lead to malfunction of the 
electrical conduction of the heart and the generation of arrhythmias. The most 
common arrhythmia is ventricular fibrillation (VF), where each ventricular myocyte 
contracts independently and this uncontrollable twitching of the muscle fibers 
prevents blood from being ejected from the heart in a regular mode.
1.2 Treatment of Myocardial Infarction
Patients who survive myocardial infarction must undergo significant surgical 
intervention following their ischemic event to avoid reoccurrence. The main 
surgical approaches to the treatment of patients who suffer heart attacks focus on 
restoring sufficient blood flow to the myocardium. One of the techniques used 
unblocks the arteries which have become occluded and this may be achieved 
using angioplasty, atherectomy or a stent procedure. The alternate approach to 
restore blood flow to the myocardium is to ‘by-pass’ the blocked vessel. Bypass 
surgery uses arteries or veins removed from other areas of the body, commonly 
the legs or the chest. These vessels are known as grafts and they reroute the 
blood supply around the blocked coronary arteries. All of these procedures 
increase blood flow to the heart and reduce the risk of further myocardial infarction.
Patients who suffer myocardial infarction are likely to follow a strict drug 
regimen for the remainder of their lives. Numerous therapies are available and 
combination therapy is commonly used to achieve the optimal therapeutic effects 
(Carson, 2000). There are a number of therapies that are prescribed after a patient 
has experienced a myocardial infarction in order to prevent further ischemic 
events. These preventive treatments include the use of anticoagulants e.g. 
heparin, and antiplatelet agents, e.g. aspirin, both of which reduce the potential for 
blood clots to form (Wu et al., 2009;Grosser et al., 2006;Hennan et al., 2001). The 
statins e.g. rosuvastatin, are blood cholesterol- lowering drugs that generally 
reduce levels of low density lipoprotein (LDL) and raise high density lipoprotein 
(HDL) cholesterol (Oui et al., 2009). These agents reduce the formation of 
atherosclerotic plaques and consequently, minimize the risk of ischemic heart 
disease. Interestingly, a recent trial focused on the treatment of healthy individuals 
with statin therapy demonstrated a reduced incidence of major cardiovascular 
events in this population (Ridker et al., 2009).
Other pharmacological strategies are directed towards alleviating the risk 
factors which increase the likely incidence of myocardial infarction such as high 
blood pressure. An example of this type of therapy is the use of the angiotensin- 
converting enzyme (ACE) inhibitors e.g. captopril and enalapril. ANG II is formed 
from angiotensin I by the action of ACE along the luminal lining of blood vessels 
and in the interstitium of the heart. ANG II is a potent vasoconstrictor and can 
directly induce arrhythmia (De Mello, 2001;Harada et al., 1998). ACE inhibitors 
attenuate the formation of ANG II and therefore oppose ANG ll-induced effects.
dilating blood vessels and reducing vessel resistance (Bakris, 2001). ANG II 
receptor blockers, e.g. losartan and valsartan are also used in the treatment of 
high blood pressure and heart failure, but rather than lowering the levels of ANG II 
like the ACE inhibitors, they function by preventing the effects of ANG II in the 
heart and blood vessels by blocking ANG II receptor activation on myocytes, 
nerves and vascular smooth muscle (Berry et al., 2001a;MaassenVanDenBrink et 
al., 1999). Beta blockers, e.g. atenolol and metoprolol are a common therapy for 
patients who have already suffered a myocardial infarction. These drugs block the 
activation of p-adrenergic receptors, reducing heart rate, cardiac output and as a 
result reduce the metabolic demand placed upon the heart (Adamson and Gilbert, 
2006). Beta blockers are effective in lowering blood pressure and also in the 
treatment of cardiac arrhythmias (Bohm and Maack, 2000). Calcium channel 
blockers, e.g. nifedipine and verapamil, are effective in reducing the influx of Ca^  ^
into the myocardium and the smooth muscle of blood vessels and exert negative 
inotropic and chronotropic effects (Gattis and O'Connor, 2000). These drugs are 
effective in lowering blood pressure and in the prevention of arrhythmias. Another 
class of drugs which are effective in the treatment of cardiovascular disease are 
the diuretics, e.g. amiloride and spironolactone. These therapies reduce the 
circulating blood volume by removing excess water and Na^ at the kidney and thus 
reduce the workload of the heart (Cadnapaphornchai et al., 2001). Crucially, all of 
these surgical and pharmacological therapies must be combined with marked 
changes in lifestyle in order for patients to attain effective recovery.
1.3 Development of a New Therapeutic Strategy
All the surgical approaches to the treatment of myocardial infarction are 
profoundly invasive. Angioplasty has formed an integral part of the treatment of 
coronary disease for over 30 years (Meier et al., 2003). However, a recent study 
suggested angioplasty does not significantly increase life expectancy and 
therapeutic outcome when combined with pharmacotherapy and lifestyle changes 
as opposed to non-surgical therapies alone (Boden et al., 2007). The 
pharmacological treatment of myocardial infarction and ischemia has developed 
into a combined preventive and symptomatic management strategy. Although a 
number of treatments are currently available, a significant degree of morbidity and 
mortality are still associated with myocardial infarction. It is also important to note 
that patients can often develop tolerance and desensitization to pharmacological 
interventions. A number of drug therapies are associated with unpleasant side 
effects leading to discontinuation of use (Schoolwerth et al., 2001;Pitt et al., 
2000;Goldberger et al., 2008;Hunt, 2005). The invasive nature of surgical 
treatments and the problematic use of current pharmacological treatments support 
the development of new approaches to the management of myocardial infarction 
and ischemia.
Notably, myocardial ischemia is associated with increased sympathetic 
nerve activity to the heart (Schomig et al., 1995). Increased sympathetic activity is 
believed to contribute substantially to the occurrence of arrhythmias in patients 
with coronary heart disease and therefore make sympathetic intervention an 
attractive prospect for new therapies (Floras, 2003). Evidence that the incidence of
sudden cardiac death is significantly reduced by p-adrenoceptor blockade, but not 
by anti-arrhythmic agents such as flecainide or encainide (Richardt et al., 1991) 
supports this notion. Indeed, increased sympathetic activity in myocardial ischemia 
is associated with the increased efflux of catecholamines. Therefore, reducing the 
excessive release of catecholamines during myocardial ischemia represents a 
viable and effective therapeutic strategy in cardiovascular conditions characterized 
by hyperadrenergic activity. A greater understanding of the signaling involved in 
the attenuation of excessive catecholamine release from cardiac sympathetic 
nerves may significantly contribute to the development of novel therapeutic 
approaches to the treatment of cardiovascular disease.
1.4 Norepinephrine: Synthesis and Regulation
The autonomic nervous system is concerned with the involuntary 
maintenance of homeostasis. Preganglionic neurons of the autonomic system 
arise in the central nervous system and extend to ganglions in the body, where 
they synapse with postganglionic neurons which innervate effector organs. The 
sympathetic branch of the autonomic nervous system is responsible for the 
mobilization of the body’s resources in response to stress. These responses are 
commonly acknowledged as the ‘fight or flight’ responses as they prepare the body 
for vigorous activity. Stimulation of the sympathetic nervous system leads to 
increased heart rate, blood pressure, cardiac output, constriction of the blood 
vessels and dilation of the pupils and the airway. Sympathetic activation also 
stimulates the conversion of glycogen to glucose in the liver and slows peristalsis
in the gastrointestinal tract. The release of epinephrine from the adrenal medulla 
into the blood ensures that all cells of the body are exposed to sympathetic 
stimulation even if no postganglionic neurons reach them directly. In contrast, the 
parasympathetic system serves the opposite function and restores the resting 
state by lowering heart rate and blood pressure, constricting the pupils, increasing 
blood flow to the skin and viscera and peristalsis in the gastrointestinal tract.
NE is the catecholamine that serves as the principal neurotransmitter in the 
sympathetic nervous system. The synthesis of NE begins with the active transport 
of tyrosine into sympathetic neurons where it is hydroxylated by tyrosine 
hydroxylase to form DOPA (3, 4-dihydroxyphenylalanine). This conversion is the 
rate-limiting step for NE synthesis. DOPA is then converted into dopamine (DA) by 
the action of the cytosolic DOPA decarboxylase. The newly formed DA is 
transported into vesicles and converted to NE by dopamine p-hydroxylase. Once 
synthesized, NE is stored with ATP in vesicles. The depolarization of the axonal 
membrane following the arrival of an action potential evokes the influx of Ca^^ via 
voltage-operated channels (VOCC). Elevated [Ca^ ]^i causes the vesicles 
containing NE to migrate to the axonal membrane. Vesicles fuse with the 
membrane and expel their contents, allowing NE to diffuse from the vesicle out 
into the extracellular junction. Once released, NE binds to postjunctional 
adrenoceptors which mediate responses in the effector tissue. The important 
interactions made by NE in the context of cardiovascular disease are made with 
Qi-adrenoceptors and Pi-adrenoceptors. The activation of oi-adrenoceptors 
produces vasoconstriction of the vasculature and activation of pi-adrenoceptors
increases myocardial contractility, heart rate, automaticity, and atrioventricular 
conduction.
Several mechanisms regulate the levels of free NE at the neuronal junction. 
Released NE binds to prejunctional 0 2 -adrenoceptors which are Gi/o coupled and 
reduced the influx of Ca^  ^ into sympathetic neurons and thus negatively modulate 
NE release. However, the majority of NE released at sympathetic nerve terminals 
is transported back into the axon by the NE transporter (NET). In addition, some of 
the released NE diffuses into capillaries and is transported away from the tissue by 
the circulation. The remaining NE is taken up by the postjunctional tissue and 
metabolized by the intracellular enzymes catechol-O-methyltransferase (COMT) 
and monoamine oxidase (MAO). COMT is present in the postsynaptic neuron and 
catalyses the conversion of NE to normetanephrine. MAO is present on the outer 
membrane of mitochondria and catalyses the oxidative deamination of NE to 3, 4- 
dihydroxyphenylglycol (Eisenhofer et al., 2004).
1.5 Norepinephrine Release in Myocardial Ischemia
In myocardial ischemia, there is increased sympathetic drive to the heart 
and excessive release of NE. The NE released by sympathetic nerve endings in 
the heart increases coronary vascular resistance via constriction of vascular 
smooth muscle mediated by of oi-adrenoceptor activation. The excessive release 
of NE also increases cardiac output via a positive chronotropic and inotropic effect 
on the myocardium due to the activation of pi-adrenoceptors. These effects 
increase the metabolic demand placed upon the heart and therefore exacerbate
the primary ischemia. The excessive release of NE from sympathetic nerve 
endings in myocardial ischemia is also a major contributor to the generation of 
cardiac arrhythmias because it produces a surge in intracellular Ca^  ^in pacemaker 
cells, specialized conducting tissue and myocytes. This surge in intracellular Ca^  ^
is caused by the inositol 1,4,5-trisphosphate (IP3)-induced mobilization of Ca^’" 
from intracellular stores following the activation of oi-adrenoceptors. A further 
elevation in intracellular Ca^  ^ arises from increased opening probability of VOCC 
as a result of increased phosphorylation of these channels by Pi-adrenoceptor 
activation. The combination of these factors generates an overload of intracellular 
Ca^  ^and ultimately produces uncoordinated myocyte contraction and arrhythmias.
1.6 GENERAL AIM
Our laboratory is interested in the role played by endogenous modulators of 
NE release from sympathetic nerves and the interaction between these nerves and 
local mast cells in myocardial ischemia. Accordingly, the general aim of this thesis 
was to develop an understanding of the signaling associated with the 
cardioprotective, anti-adrenergic effects of H3R and to determine the relationship 
between sympathetic nerves and mast cells in myocardial ischemia.
Hvpothesis: It is hypothesized that H3R activation is cardioprotective in that: 
a) it may reduce NE exocytosis by decreasing calcium influx into sympathetic 
nerves, and b) it may prevent the activation of a local cardiac renin-angiotensin 
system via reduction of neuropeptide-mediated mast cell renin release.
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Gfij^DEPENDENT INHIBITION OF VOLTAGE-OPERATED CALCIUM 
CHANNELS PLAYS A PIVOTAL ROLE IN THE ANTI-EXOCYTOTIC EFFECT 
OF HISTAMINE H3-RECEPTOR ACTIVATION
2. INTRODUCTION
2.1. Histamine and the Heart
Histamine is a basic amine, synthesized from histidine by the action of L- 
histidine decarboxylase and is an important mediator of inflammation. Histamine is 
present in the vast majority of tissues where it is stored in mast cell granules. 
Although histamine is present in a variety of other cells including basophils, 
platelets, enterochromaffin cells, endothelial cells and neurons (Hill, 1990), in the 
heart it is almost exclusively found in mast cells (Patella et al., 1995). Unconfirmed 
reports also suggest the presence of histamine in sympathetic nerves (Li et al., 
2006;Li et al., 2007).
There are four histamine G-protein coupled receptor (GPGR) subtypes Hi, 
H2, H3 and H4 receptors (HiR, H2R, H3R and H4R) (Hill et al., 1997). All the 
histamine receptor subtypes are comprised of seven transmembrane domains. 
The more recently discovered H4R play a role in mast cell chemotaxis and may be 
responsible for their accumulation in allergic tissues (Hofstra et al., 2003). HiR 
activation is responsible for the classical inflammatory effects associated with 
histamine including vasodilation, increased capillary permeability and contraction 
of visceral smooth muscle. These responses are mediated by the phosphoinositide 
signaling pathway operating through a pertussis-toxin insensitive G-protein
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believed to belong to the Gq/n class (Jutel et al., 2005). In contrast, the H2R are 
coupled to adenylyl cyclase via a Gg-protein and their activation elevates 
intracellular levels of cyclic adenosine monophosphate (cAMP), inducing gastric 
acid secretion and cardiac stimulation. Although histamine can act directly upon 
arrhythmogenic HiR and H2R (Wolff and Levi, 1986), a beneficial relationship 
exists between the release of pre-formed histamine from cardiac mast cells and 
the attenuation of NE release from sympathetic nerves during myocardial 
ischemia. This beneficial interaction between mast cells and sympathetic nerves 
involves activation of H3R present on cardiac sympathetic nerve endings.
2.2. Histamine Hs-Receptors
The structural identification and cloning of human H3R led to the 
subsequent cloning of homologous receptors in other species including guinea pig, 
mouse and rat as well as numerous receptor isoforms (Chen et al., 
2003;Lovenberg et al., 2000) (Wellendorph et al., 2002). H3R are 445 amino acids 
in length and share only limited sequence similarity with other members of the 
GPGR family. The Kd values of HiR, H2R and H3R for histamine are 160 nM, 1 pM 
and 40 nM, respectively (Malinowska et al., 1998) indicating that H3R become 
activated at lower concentrations of free histamine. H3R are linked to a pertussis 
toxin-sensitive G/Go G-protein (Endou et al., 1994;Hill et al., 1997). Activation of 
this pathway leads to inhibition of adenylyl cyclase, reduced cAMP formation and 
diminished protein kinase A (PKA) activity (Seyedi et al., 2005). H3R are 
predominantly found pre-synaptically in histamine-containing neurons in the brain.
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Initial evidence supporting the existence of the receptor stemmed from the high 
affinity binding of radio-labeled histamine to rat brain membranes (Arrang et al., 
1990). Early investigations designed to elucidate the function of the H3R included 
identification of an inhibitory role in adrenergic neurotransmission in the mesenteric 
artery (Ishikawa and Sperelakis, 1987). These findings were supported by data 
obtained in electrophysiological studies in guinea-pig ileum smooth muscle 
(Tamura et al., 1988). The inhibitory effect of H3R activation was later 
characterized with the use of the selective agonist (R)a-methylhistamine (Luo et 
al., 1991). Exposure to (R)a-methylhistamine inhibited the positive inotropic effect 
of electrical stimulation of guinea-pig atria. H3R activation also suppresses both the 
tachycardie responses to medulla oblongata and spinal cord stimulation (Hey et 
al., 1992;Malinowska and Schlicker, 1993). The generation of mice devoid of H3R 
(H3R'^ ‘) was an important addition to the functional investigation of the receptors 
(Toyota et al., 2002). H3R'^ ' display decreased spontaneous locomotor activity and 
thermoregulation and express normal levels of the dopamine, NE, and serotonin, 
but reduced histamine expression.
2.3. Mechanisms of Norepinephrine Reiease
Myocardial ischemia is associated with enhanced NE overflow into coronary 
effluent (Imamura et al., 1994). Excessive release of NE from sympathetic nerve 
terminals can produce severe ventricular arrhythmias, cardiac dysfunction and 
sudden cardiac death as introduced briefly in Chapter 1. During myocardial 
ischemia, depolarization of cardiac sympathetic nerve endings causes the
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activation of VOCC resulting in a surge in intracellular Ca^ .^ The rise in 
intracellular Ca^ "" within the neuron stimulates the migration of NE-containing 
vesicles to the cell membrane. The vesicles fuse with the membrane and release 
NE from the nerves into the synaptic cleft. The release of NE from sympathetic 
nerve terminals following the arrival of a depolarizing action potential causes 
activation of post-junctional adrenergic receptors. NE activates pi-adrenoceptors 
which are abundantly expressed in the heart, specifically in the sinoatrial node (SA 
node), atrioventricular node (AV node) and cardiac myocytes. Stimulation of the 
pi-adrenoceptor produces a cAMP-mediated increase in intracellular Ca^  ^ which 
increases activity at both the SA node and AV node, causing increased heart rate 
and conduction velocity. NE also activates oi-adrenoceptors present in the 
plasma membrane of vascular myocytes of arteries which in turn stimulate 
phospholipase C. The resultant increased phosphoinositol (PI) turnover leads to 
I Pa-induced release of Ca^  ^from intracellular stores. The elevation in intracellular 
Ca^  ^ produces vasoconstriction in these arteries, decreasing coronary flow and 
precipitating ischemia thus amplifying the Pi-adrenoceptor-mediated 
arrhythmogenic effects.
There are two mechanisms underlying NE release from sympathetic nerve 
endings in the heart. These are Ca^^-dependent exocytosis and Ca^^-independent 
(carrier-mediated) release of NE. Under physiological conditions and in acute 
myocardial ischemia NE is released from sympathetic nerve endings by the Ca^*- 
dependent exocytotic mechanism (see Figure 1.1). This release is linked to a rise 
in [Ca^^i entering via transmembrane VOCC and Ca^  ^ released from intracellular
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Figure 1.1. The exocytosis of NE from cardiac sympathetic nerve 
endings in acute myocardial ischemia. (Levi and Smith, 2000) 
Abbreviations: A1, adenosine A1-receptor; 0 2 , 0 2 -adrenoceptor; DMI, 
desipramine (a NE transporter inhibitor); MAO, monoamine oxidase.
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Figure 1.2. The events that trigger carrier-mediated NE release from 
cardiac sympathetic nerve endings and induce ventricular arrhythmias 
in protracted myocardial ischemia. (Levi and Smith, 2000) Abbreviations: 
AC, adenylyl cyclase; ARR, arrhythmias; DMI, desipramine (a NE 
transporter inhibitor); EIPA, 5-(N-ethyl-N-isopropyl)amiloride (a Na /^H"" 
exchanger inhibitor); NHE, Na /^H  ^exchanger; PLC, phospholipase 0; SNE, 
sympathetic nerve ending; VMAT, vesicular monoamine transporter.
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stores (Imamura et al., 1994). In contrast, the carrier-mediated mechanism (see 
Figure 1.2) of NE release predominates during protracted ischemia and requires 
the reversal of the neuronal NE re-uptake system (Schomig, 1990). Reversal of 
the NET results in a substantially increased efflux of NE from sympathetic nerve 
endings and the induction of severe arrhythmias. Prolonged exposure of 
sympathetic nerve terminals to ischemia evokes significant hypoxia, ATP depletion 
and a reduction in intracellular pH, all key factors in the generation of carrier- 
mediated release of NE into the interstitium (Kübler and Strasser, 1994). The 
acidified interior of sympathetic nerves opposes the vesicular storage of free NE, 
normally reliant on the development of a pH gradient across the vesicular 
membrane (maintained by an ATP dependent H'' pump). A shortage of ATP and a 
reduced axoplasmic pH as a result of anaerobic glycolysis render this pump 
redundant allowing the accumulation of free NE. The efflux of free NE is mediated 
by NET which is Na"" and Cl' dependent. The exchange of Na"" for H  ^ via the 
Na^H* exchanger (NHE) opposes the build up of intracellular H  ^and the lowering 
of pH. However, the raised level of intracellular Na^ increases NET availability to 
the axonal interior and enhances the affinity of axoplasmic NE for the carrier 
(Sammet and Graefe, 1979). When NE, Na'" and Cl' bind to the carrier, the efflux 
of NE proceeds.
In acute myocardial ischemia intracellular Ca^ "" regulation, and therefore the 
Ca^ "" sensitivity of the exocytotic machinery, is the major modulatory element in the 
exocytosis of NE. In contrast, in protracted ischemia the regulation of NHE activity 
is the most significant factor influencing carrier-mediated efflux of NE.
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2.4. A Role for H3R in Myocardial ischemia
Myocardial ischemia leads to the generation of reactive oxygen species 
(ROS). These radicals activate cardiac mast cells, releasing histamine into the 
myocardial interstitium and along the lining of the coronary vessels of the heart 
(Frangogiannis and Entman, 2000;Frangogiannis et al., 2002;Steiner et al., 2003). 
The anoxic human heart has been shown to release endogenous histamine (Hatta 
et al., 1997) and histamine spillover into the coronary effluent is markedly 
increased during reperfusion following a period of global ischemia (Imamura et al., 
1994). Inasmuch as these findings indicate that under ischemic conditions the 
noradrenergic terminals of the heart are exposed to high levels of histamine, the 
pharmacological identification of H3R in mouse (Koyama et al., 2003b), guinea-pig 
(Endou et al., 1994), canine (Seyedi et al., 1996) and human heart (Imamura et al., 
1995a) clearly suggest a functional role for H3R in this organ. The exogenous 
application of histamine combined with specific HiR and H2R antagonists 
significantly inhibits the tachycardia and release of NE elicited by sympathetic 
nerve stimulation in the guinea pig heart (Imamura et al., 1994). These effects are 
prevented by the application of a specific H3R antagonist, thioperamide (Arrang et 
al., 1987). However, it is noteworthy that in this study, sympathetic nerve 
stimulation alone produced only a modest increase in histamine overflow which 
would be unlikely to activate H3R. This implies that H3R remain quiescent under 
physiological conditions, yet available for activation by histamine released during 
myocardial ischemia. Accordingly, H3R mediate a redundant feedback mechanism 
of NE release under normal physiological conditions (Levi and Smith, 2000). In
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contrast, in ischemic conditions H3R play an integral role in modulating cardiac 
dysfunction, operating as inhibitory hetero-receptors at sympathetic nerve endings 
in the heart by attenuating the release of NE.
Evidence supporting a cardioprotective role for H3R stems from the fact that 
H3R activation reduces the exocytosis of NE evoked by K'^-induced depolarization 
of sympathetic nerve endings (synaptosomes) in human heart (Imamura et al., 
1995b). The release of NE in this study was shown to be exocytotic as it was 
prevented by treatment with both a specific VOCC blocker and a protein kinase 
inhibitor. Moreover, H3R are negatively coupled to NHE activity, as demonstrated 
using an intracellular pH indicator dye (Silver et al., 2001). In this study, a selective 
H3R agonist, imetit (Garbarg et al., 1992) markedly reduced NHE activity in these 
cells and thioperamide, a specific H3R antagonist (Arrang et al., 1987) abolished 
the imetit-induced action. Notably, mice lacking H3R exhibit a greater incidence 
and longer duration of ventricular fibrillation when subjected to 
ischemia/reperfusion than wild-type control hearts (Koyama et al., 2003b).
2.5. Voltage-Operated Calcium Channels and H3R Activation
Exocytotic release of NE is dependent on the entry of Ca^ "" through VOCC, 
including the N-type channel (Lipscombe et al., 1989). Reduced NE exocytosis 
from sympathetic nerve endings resulting from H3R activation has previously been 
linked to inhibition of N-type VOCC activity (Endou et al., 1994). These findings are 
supported by data obtained from histaminergic neurons from rat hypothalamus 
using voltage-damp measurements (Takeshita et al., 1998). Furthermore, H3R-
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mediated attenuation of NE exocytosis is associated with a marked reduction in 
intracellular Ca^ "" (Silver et al., 2002), reiterating the important association between 
H3R activation, intracellular Ca^ "" and the exocytosis of NE. Permeation of Ca^ "" 
through VOCC in neuronal tissue is essential to neurotransmitter release as 
previously discussed in Chapter 1.4. Furthermore, VOCC are well-known targets 
for inhibition by GPCR pathways. It is possible that entry of Ca^ "" through L-type 
Ca '^" channels may also be important in NE exocytosis and be inhibited by H3R 
activation. Indeed, a synergy of H3R activation with both N- and L-type Ca^* 
channel blockers reduced the K^-induced NE release from cardiac synaptosomes 
(Seyedi et al., 2005). Pre-synaptic receptors which modulate the depolarization- 
evoked release of NE commonly rely on a G-protein-mediated inhibition of VOCC. 
Indeed, a2-adrenoceptors on sympathetic nerves attenuate NE release by 
inhibiting VOCC (Boehm and Huck, 1995). Moreover, a2-adrenoceptor agonists 
prevent field stimulation-induced release of NE in chick sympathetic neurons by 
reducing intracellular Ca^ "" via VOCC inhibition (Boehm et al., 1996).
Useful tools in understanding the roles of VOCC in cardioprotection are the 
specific calcium channel blockers. N-type calcium channels which are prominent at 
sites of neurotransmission (hence the designation N) are blocked by w-conotoxin 
GVIA (w-CTX) originally isolated from the venom of the piscivorous cone snail, 
Conus geographicus (Olivera et al., 1984). The binding of w-CTX to voltage- 
dependent calcium channels and its effects on the function of these channels has 
been discussed in detail (Sher et al., 1991). L-type calcium channels are important 
in excitation-contraction coupling in skeletal, smooth and cardiac muscle and
20
hormone secretion in endocrine cells (Hur et al., 2001;Marcantoni et al., 2007). 
Dihydropyridine antagonists including nifedipine and nitrendipine are selective 
blockers of L-type calcium channels (Nowycky et al., 1985).
2.6. Gfi/Dimer Modulation of Voltage-Operated Calcium Channels
The precise nature of Ca^ "" signaling associated with H3R activation and 
downstream attenuation of NE exocytosis remains to be fully characterized. 
Considerable debate has centered on which G-protein subunit is responsible for 
coupling GPCR activation with Ca^  ^ influx through VOCC (Dolphin, 1998). It is 
important to consider all components of trimeric G-proteins when investigating H3R 
signaling. Following GPCR activation, the Gpy component of the heterotrimeric G 
protein is also liberated. Free Gpy subunits bind and regulate multiple target 
proteins including phospholipase C p2 and p3, phosphoinositide 3 kinase, N-type 
Ca^ "" channels and inwardly rectifying K"" channels (Bonacci et al., 2006). A direct 
coupling of the GPy subunit to VOCC may contribute to H3R signaling as well as 
the PKA-mediated effect of Goj (Seyedi et al., 2005). Interestingly, H3R activation 
is linked to Gpy-mediated stimulation of the MAPK-PLA2 cascade and has been 
shown to culminate in PGE2-derived anti-exocytotic effects (Levi et al., 2007). In 
addition, the Gpy dimer is also known to reduce adenylyl cyclase activity (Taussig 
et al., 1993) and it is also therefore plausible that GPy may have a role in H3R- 
mediated decreases in cAMP. The direct coupling of GPy subunits with the 
exocytotic fusion machinery at the pre-synaptic terminal downstream of Ca^ "" entry 
may be another potentially important interaction in H3R-induced the attenuation of
21
NE exocytosis (Blackmer et al., 2001). In addition, there is also the potential for 
direct coupling of the Gpy subunit to VOCC (Herlitze et al., 1996;lkeda, 1996) as it 
is already well established that the dimer inhibits N-type VOCC activity (Dolphin, 
2003). Gpy-induced inhibition of VOCC is thought to be mediated by direct 
interaction of the Gpy dimer with the pore-forming a1-subunit of the channel at a 
binding site on the intracellular loop region between domains I and II (359-389). 
Voltage-dependent inhibition of VOCC is believed to be the result of disruption of 
channel subunit interactions. Regions of the C terminus of the VOCC have also 
been implicated in the interaction between channel subunits and the GPy dimer (Li 
et al., 2004).
A useful tool in the investigation of the role played by the GPy subunit in 
neuronal signaling is the p-ARKI -(495-689)-polypeptide Gpy scavenger, derived 
from the GPCR kinases (GRKs) (Koch et al., 1994;Dickenson and Hill, 1998). 
GRKs are cytosolic enzymes with membrane-bound receptor substrates. GRKs 
were identified in functional assays which revealed their ability to phosphorylate 
and regulate specific GPCRs, i.e. the p2-adrenergic receptor. GRKs are composed 
of a central catalytic domain with amino and carboxyl-terminal domains of variable 
length. p-ARKI is a GRK that is regulated by interaction with the py subunits of 
heterotrimeric G-proteins and is widely distributed throughout the mammalian 
central nervous system, suggesting broader roles in regulating a variety of 
neurotransmitter receptors. The GPy dimer binding domain has been localized to a 
125 amino acid region. At the distal end of this binding domain there is a region 
where 19 residues from the C-terminus of p-ARKI are located. A minigene
22
construct encoding the last 195 amino acids of p-ARKI (Gly'^ ^^ -Leu®®®) and 
capable of expressing a polypeptide with the ability to block GPy signaling has 
proved a useful tool in assessing the role of Gpy subunits in GPCR activation of 
signaling pathways (Koch et al., 1994).
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2.7 AIM 1
The modulation of NE release from sympathetic nerves represents a novel 
therapeutic approach to the treatment and prevention of complications which occur 
as a result of myocardial ischemia. H3R activation is cardioprotective in that it 
attenuates NE release. Hence, further elucidation of the signaling pathway 
involved in this attenuation will allow a greater and more accurate appreciation of 
the mechanisms by which these therapeutic outcomes can be realized.
Hvpothesis: The cardioprotective anti-exocytotic function of H3R action stems from 
the liberation of Gi/o-derived py dimer, which exerts a direct inhibition of VOCC on 
sympathetic nerves. The result is reduced Ca^  ^ influx and the attenuation of 
excessive NE exocytosis in myocardial ischemia. Inasmuch as the reduction of NE 
release is protective in myocardial ischemia, validation of this hypothesis will 
further characterize the signaling cascade associated with H3R-mediated 
attenuation of NE release in the heart.
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2.8 MATERIALS AND METHODS
Cell Culture
The rat pheochromocytoma PC12 cell line purchased from ATCC (catalog 
number ATCC CRL 1721) maintained in Dulbecco's modified Eagle's media 
(DMEM) plus 10% fetal bovine serum (PBS), 5% donor horse serum (DHS), 1% L- 
glutamine, and antibiotics at 37°C in 5% CO2 . The differentiating protocol involved 
plating PCI 2 cells on tissue culture plates coated with collagen (rat tail type-VII, 
Sigma) combined with exposure to low serum media containing 1% PBS, 0.5% 
DHS, 1% L-glutamine, and antibiotics supplemented with 2.5S-NGF (Harlan 
Bioscience, Indianapolis, IN, USA). Culture media and NGF were replenished 
every 2 days. The human H3R, HRH3, was cloned into pCI-neo vector (Promega) 
and this was generously donated by Dr. T. W. Lovenberg. PCI 2 cells were 
transfected with the HRH3pCI-neo vector using Lipofectamine™ 2000 (Invitrogen, 
Carlsbad, CA) following the manufacturer’s protocol. The human beta receptor 
kinase 1, ADRBK1, was cloned into the pRK5 vector (Clontech) and this was 
obtained from Dr. R.J. Lefkowitz. PCI2 cells were transfected with the 
ADRBK1 pRK5 vector using Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA) 
following the manufacturer’s protocol. PCI2 -H3 and PCI2 -H3/P-ARKI cell lines 
were selected and maintained in selection media containing 500 pg/ml G418 
sulfate (Mediatech, Herndon, VA) and/or zeocin (Invitrogen) respectively.
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Reverse Transcription PCR
Total RNA was isolated from PC12 and PCI2 -H3 cells using the TRIzol 
RNA purification kit (Invitrogen). cDNAs were synthesized from total RNA using 
Superscript II reverse transcriptase (Invitrogen) and random primers as described 
by the manufacturer. Polymerase chain reaction (PCR) was used to detect the 
H3R mRNA expression with cDNA using Platinum Tag DNA polymerase 
(Invitrogen) and either PC12 or PCI2 -H3 as templates with P1: 5'- 
CTCTGCAAGCTGTGGCTGGTGGTAGACTACCTACTGTGTG-3' and P2: 5'- 
CTTCTTGTCCCGCGACAGCCGAAAGCGCTGGGTGATGCTT-3' as primers 
(Invitrogen). PCRs were performed under conditions of 94°C, 40 s; 65°C, 40 s; 
72°C, 2 min for 40 cycles. As control, total cDNA from HeLa RNA was used as the 
template for amplification of a 353-bp segment of p-actin mRNA in a parallel PCR 
reaction. The PCR products were run on a 1.5% agarose gel, stained with ethidium 
bromide and visualized under UV light.
Western blotting
A TRIzol RNA purification kit (Invitrogen) was used to prepare cell lysates 
(20 pg) from PCI2 -H3 and PCI2 -H3/P-ARKI cells and these were separated by 
SDS/PAGE 10-20% acrylamide gel and transferred to a PVDF membrane 
(Millipore). Following transfer, the membrane was washed with Tris-buffered saline 
(TBS) and blocked for 2 h at room temperature in blocking buffer (TBS containing 
0.1% Tween 20, 5% (w/v) non-fat dry milk). Blots were then incubated overnight at 
4°C with anti-p-ARK1 primary antibody (Epitomics) at 1:500 dilution in 5% (w/v)
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bovine serum albumin dissolved in TBS-Tween 20 (0.1%). The primary antibody 
was removed and the blot extensively washed with TBS/Tween 20. Blots were 
then incubated for 2  h at room temperature with horseradish peroxidase-coupled 
anti-rabbit IgG (Cell Signaling Technology) at a 1:3000 dilution in blocking buffer. 
Following removal of the secondary antibody, blots were extensively washed as 
above and developed using the Enhanced Chemiluminescence detection system 
(Pierce) followed by exposure to X-ray film (Biomax MR). 
cAMP Measurement
Cellular cAMP accumulation was measured in PCI2 -H3 and PCI2 -H3/P- 
ARK1 cells seeded in 96-well plates and differentiated with NGF (100 ng/mL) for 5- 
7 days. After a 20-min treatment with the cAMP phosphodiesterase inhibitor 3- 
isobutyl-1 -methylxanthine (IBMX) (2 mM), cells were incubated for 5 min with or 
without the H3R agonist imetit ( 1 0 0  nM), either alone or in combination with the 
H3R antagonist clobenpropit (CBP) (50 nM). Cells were incubated with CBP for 5 
min before the addition of imetit. Intracellular cAMP levels were then enhanced 
with forskolin (10 pM) for 20 min. The incubation buffer was immediately aspirated, 
cells were lysed and intracellular cAMP levels determined using a cAMP Biotrak 
EIA kit (Amersham Biosciences) following the manufacturer's protocol. All drugs 
were constituted in HEPES-buffered Na"" Ringer’s solution (140 mM NaCI, 5 mM 
KCI, 10 mM HEPES, 2 mM CaCb, 1 mM MgClz, pH 7.4).
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Dopamine Assay
PCI2 -H3 and PCI2 -H3/P-ARKI cells were cultured in 12-well plates and 
differentiated with NGF (100 ng/ml) for 5-7 days. Cells were incubated with drugs 
for 5 min. When antagonists were used, samples were incubated with antagonist 
for 5 min before incubation with agonist. For PTX treatment, cells were incubated 
for 24 h with PTX (200 ng/ml) prior to performing the assay. Dopamine exocytosis 
was elicited by incubating samples for 5 min with 100 mM (osmolarity was 
maintained constant by adjusting the NaCI concentration), phorbol 12-myristate 
13-acetate (PMA, 300 nM) or for 20 min with forskolin (10 pM). At the end of the 
incubation period, aliquots of the supernatant and cell lysates (after a 30-min 
treatment with 0.3% Triton X-100) were taken from each well and analyzed for 
dopamine content by HPLC with electrochemical detection as previously described 
(Seyedi et al., 2005) with a 6  min retention time.
Electrophysiology
Whole-cell voltage-damp studies were performed on PCI 2 cells. The cells 
were transferred to 22 x 22 mm glass coverslips coated with poly-L-lysine and 
collagen and differentiated with NGF (50 ng/ml) for 3-7 days before use in voltage- 
damp experiments. Bath solution was (in mM): 20 BaCb, 125 N-methyl-D- 
glucamine, 10 HEPES (pH 7.5). Pipettes had resistances of 6-9 MQ when filled 
with intracellular solution containing (in mM): 100 N-methyl-D-glucamine, 20 
TEACI, 10 EGTA, 2 MgCb, 10 glucose, 2 NazATP, 10 HEPES (pH 7.35). 
Fragments of coverslips were transferred to a recording chamber and the media
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rinsed off with bath solution. Following adoption of whole-cell configuration, 
currents were recorded either in the absence (baseline) or presence of drugs. 
Cells were held at -40 mV and subjected to 200 ms test pulses from -40 mV to +40 
mV in 10 mV increments every 30 s. Recordings were performed at 22°C to 25°C 
using an 1X50 inverted microscope (Olympus), a Multiclamp 700A Amplifier, a 
Digidata 1300 Analog/Digital converter and pClamp9 software (Axon Instruments). 
All recordings were lowpass bessel filtered and those with leak currents greater 
than 20 pA or an access resistance greater than 25 MQ discarded. Current-voltage 
relationships were obtained by measuring the peak current during depolarizing 
pulses. Data analysis was performed using Clampfit 9 (Axon Instruments). Current 
density was calculated by dividing the current (pA) recorded from each individual 
cell by the capacitance (pF) of that cell. Calcium current ( Ic a )  activation was 
described by fitting a single exponential function to the current trace from the 
beginning of the pulse to the point where a steady-state level was reached so as to
obtain the time constant of activation (Tact).
Reagents
CBP, imetit, IBMX, NGF, w-CTX, PMA and PTX were prepared in aqueous 
solution while DMSG was the vehicle for IBMX, forskolin and nifedipine. The anti- 
Py peptide was obtained from Anaspec, imetit from Tocris Bioscience and PMA 
from LC Laboratories. All other chemicals were reagent grade and purchased from 
Sigma Aldrich.
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Statistics
cAMP levels were expressed as mean absolute values ± SEM. Dopamine 
release values were expressed as mean percent increases above basal level ± 
SEM. Current density was expressed as mean ± SEM, with n specifying the 
number of independent experiments. Statistical significance was assessed using 
Student’s t test or one-way AN OVA followed by post hoc testing (Dunnett's test) as 
indicated in the appropriate figure legend. Significance was asserted if p<0.05.
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2.9 RESULTS
Stable expression of human H3R in PC12 cells was first ascertained by RT- 
PCR. A segment of -700 bp was amplified demonstrating the presence of H3R in 
PCI2 -H3 cells; this band was absent in non-transfected PC12 cells (Figure 2.1A). 
The transfected H3R were Gj/o-coupled as demonstrated by the loss of their anti- 
exocytotic activity after pretreatment with PTX (100 ng/ml; Figure 2.2C). 
Stable expression of p-ARKI-(495-689)-polypeptide in PCI 2 cells was determined 
by Western blotting. A band of -27 kDa confirmed the expression of p-ARKI in 
PC12-H3/P-ARK1 cells, but not in PCI2 -H3 cells (Figure 2.1 B).
The next objective was to verify the functionality of transfected H3R. 
Inasmuch as H3R are known to be negatively coupled to adenylyl cyclase via Gai 
(Lovenberg et al., 1999), it was determined that H3R activation did indeed reduce 
the formation of cAMP in PCI2-H3 cells in response to forskolin. In the presence of 
the selective agonist imetit (100 nM) (Garbarg et al., 1992) a -20-fold forskolin- 
induced (10 pM) increase in intracellular cAMP concentration was attenuated by 
70% (Figure 2.2A). Clobenpropit (50 nM), a selective H3R antagonist (Van der 
Goot et al., 1992), reduced the effect of imetit by -60% (Figure 2.2A). This 
confirmed that the G\io signaling cascade associated with transfected H3R was 
functional.
Since some forms of adenylyl cyclase are inhibited by the Gpy dimer (Tang 
and Gilman, 1991), it was important to question whether the decrease in 
intracellular cAMP concentration in the presence of imetit was due to a Gpy- 
induced diminution of cAMP-PKA activity. To evaluate this possibility, cAMP
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Figure 2.1. Detection of H3 R and over-expression of p-ARKI(495-689) minigene 
in PCI2-H3 cells. (A) Reverse-transcriptase PCR. cDNA was synthesized from total 
RNA prepared from PC12 and PCI2 -H3 cells and used as template in a PCR 
reaction. The PCR products were run on a 1.5 % agarose gel and detected under UV 
light. As controls, p-Actin primers were used in a parallel PCR reaction for 
amplification of a 353-bp segment. (B) Western blot analysis of p-ARKI (495-689) 
minigene. Cell lysates (20 pg) isolated from PCI2 -H3 and PCI2 -H3/P-ARKI cells 
were resolved by SDS-PAGE and transferred to PVDF membrane. Blotting of the 
membrane with anti-p-ARK1 monoclonal antibody (1:500) revealed a -27 kDa 
specific band. Positions of standard molecular mass markers of 26 and 37.4 kDa are 
shown on the left.
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Figure 2.2. H3R activation reduces intracellular cAMP accumulation and dopamine 
exocytosis elicited by forskolin (10 pM) in NGF-differentiated rat pheocromocytoma 
cells stably transfected with human H3R (PCI2-H3) and in PCI 2 cells transfected with 
both H3R and the Gpy scavenger p-ARKI (PCI2-H3/P-ARKI). Panels A and B; 
increases in intracellular cAMP levels; panels C and D; dopamine release, in the 
absence or presence of the H3R agonist imetit (100 nM), either alone or in 
combination with the H3R antagonist clobenpropit (CBP, 50 nM). Bars are means ± 
S.E.M. {n = 15-19 for A and B and n = 10-15 for C and D). Significantly different from 
control or forskolin (*, p<0.05 and **, p<0.01 by AN OVA followed by post hoc 
Dunnett’s test).
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accumulation and endogenous dopamine exocytosis (Chen and Westfall, 1994) 
were determined in response to forskolin, in control and HsR-activated conditions 
in PCI2 -H3 cells stably transfected with the GPy scavenger p-ARKI polypeptide 
(Koch et al., 1994) and compared with those measured in PCI2 -H3 cells. In PC12- 
H3/P-ARKI cells forskolin (10 pM) elicited a ~15-fold increase in intracellular cAMP 
concentration, which was comparable to that observed in PCI2 -H3 cells (compare 
panels A and B in Figure. 2.2). In the presence of imetit (100 nM) the increase in 
cAMP formation was attenuated by -70%; clobenpropit (50 nM) reduced the effect 
of imetit by -60% (Figure. 2.2B). Thus, H3R activation produced effects of similar 
magnitude in PCI2 -H3 and PCI2 -H3/P-ARKI cells (compare panels A and B in 
Figure 2.2), indicating that the Gpy complex does not have inhibitory effects on the 
form of adenylyl cyclase present in PCI 2 cells. Furthermore, forskolin (10 pM) 
elicited a -2- and -3-fold increase in dopamine release in PCI2 -H3 and PC12- 
H3/P-ARKI cells, respectively (Figure. 2.20 and D). H3R activation with imetit also 
significantly attenuated dopamine exocytosis (by -60%) in both PCI2 -H3 and 
PCI2 -H3/P-ARKI cells; this effect was inhibited by H3R blockade with clobenpropit 
(Figure 2.20 and D). Thus, in differentiated P012 cells stimulated with forskolin, 
the H3R-mediated decrease in cAMP and associated anti-exocytotic effect derive 
mostly from an inhibition of adenylyl cyclase by Goj and not by Gpy.
Peak Ica in POI2 -H3 cells was next measured using the conventional 
whole-cell patch-damp technique (Figure 2.3). The Ica activated at voltages equal 
or positive to -20 mV and reached a peak at +10 mV. Peak Ica was markedly 
reduced by incubation with w-conotoxin GVIA (w-OTX; 100 nM) or nifedipine (5
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pM), indicating that both N- and L-type Ca^ "" channels contribute to the Ica recorded 
in these cells (Figure 2.3). Indeed, combined treatment of the cells with nifedipine 
and w-CTX blocked 90% of Ica (Figure 2.3A). When PCI2 -H3 cells were incubated 
with imetit (100 nM), peak Ica was significantly attenuated; this response was 
antagonized by clobenpropit (50 nM) (Figure 2.3B). Stimulation of adenylyl cyclase 
with forskolin (10 pM) enhanced peak Ica by -25%; again, this current was 
markedly reduced by imetit, and clobenpropit antagonized the effect of imetit 
(Figure 2.30).
The exocytosis of endogenous dopamine was next determined in PCI2 -H3 
cells depolarized with K"" (100 mM). Depolarization with K"" elicited a -2.5-fold 
increase in dopamine release, a response curtailed by -70% by the L-type Ca^ "" 
channel antagonist nifedipine (5 pM), but not by the N-type channel antagonist w- 
CTX (100 nM) (Figure 2.4). H3R activation with imetit also significantly attenuated 
dopamine exocytosis (-30%); this effect was abolished by H3R blockade with 
clobenpropit, a further confirmation of the functionality of transfected H3R (see 
Figure 2.2A). Thus, H3R activation attenuated both peak Ica and dopamine 
exocytosis, suggesting that H3R-mediated anti-exocytotic effects could result from 
a reduced Ca^ "" influx via VOCC.
Since H3R are Gj/o-coupled and Gpy subunits are known to directly inhibit 
VOCC function (Ikeda, 1996;Herlitze et al., 1996), it was necessary to assess 
whether the Gpy dimer plays a role in the decrease in Ica and associated anti- 
exocytotic effect observed with H3R activation. Peak Ica in PCI2 -H3/P-ARKI cells 
did not differ from that recorded in PCI2 -H3 cells (Figure 2.5A). In contrast to what
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Figure 2.3. Typical peak calcium currents and normalized peak calcium current evoked 
in NGF-differentiated PCI2 -H3 cells by stepping from the holding potential of -40 mV to 
the test potential of +10 mV. Panel A: calcium current is inhibited by w-CTX (100 nM) 
and nifedipine (5pM), selective blockers of N- and L-type Ca^^-channels, respectively. 
Panel B: H3R activation with imetit (100 nM) attenuates calcium current, an effect 
prevented by the H3R antagonist clobenpropit (CBP). Panel C: Stimulation of adenylyl 
cyclase with forskolin (10 pM) increases calcium current. Incubation with imetit markedly 
reduces the forskolin-stimulated calcium current; CBP prevents this effect. Individual 
traces are from independent experiments. Bars represent means (± SEM; n=20; *, 
p<0.05, **, p<0.01 from control or forskolin by AN OVA followed by post hoc Dunnett’s 
test).
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Figure 2.4. H3 R activation attenuates endogenous dopamine exocytosis elicited by 
depolarization with (100 mM) in NGF-differentiated rat pheocromocytoma cells 
transfected with human H3R (PCI2-H3). Dopamine exocytosis is inhibited by nifedipine 
(5 pM), an L-type calcium channel blocker. The anti-exocytotic effect of imetit (100 nM) 
is prevented by the H3R antagonist clobenpropit (CBP; 50 nM) and a membrane- 
permeable phosducin-like anti-py peptide (1 pM). Bars are means ± S.E.M. {n =18-21). 
Significantly different from alone (*, p<0.05 and **, p<0.01 by AN OVA followed by 
post hoc Dunnett’s test).
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was observed in PCI2 -H3 cells, imetit failed to reduce peak Ica in PCI2 -H3/P- 
ARK1 cells, indicating that the Gpy dimer plays a role in the H3R-mediated 
reduction of Ica (compare Figs. 2.3B and 2.5A). Furthermore, the slowing of current 
activation, as demonstrated by an increase in Tact in the presence of imetit in
PCI2 -H3 cells, supports a direct Gpy-induced inhibition of VOCC (Figure. 2.3B, 
see inset) (Stephens et al., 1998). Additionally, whereas the anti-exocytotic effect 
of nifedipine was preserved in PCI2 -H3/P-ARKI cells, imetit failed to affect 
dopamine exocytosis (Figure. 2.5B), nor did imetit modify dopamine exocytosis in 
PCI2 -H3 cells incubated with a membrane-permeable phosducin-like anti-py 
peptide (1 pM) (Chang et al., 2000) (Figure 2.4). Collectively, these findings 
indicate that the H3R-mediated anti-exocytotic effect derives from the Gpy- 
dependent inhibition of Ica and not from a Py-induced inhibition of adenylyl cyclase.
Activation of protein kinase C (PKC) upon application of phorbol esters is 
known to increase Ica (Zamponi et al., 1997), an action negatively modulated by 
Gpy subunits (Ikeda, 1996;Herlitze et al., 1996). Accordingly, an assessment of 
whether H3R stimulation would attenuate PKC-activated Ica and associated 
increase in dopamine exocytosis via a Gpy-mediated effect was made. Incubation 
of PCI2 -H3 cells with phorbol 12-myristate 13-acetate (300 nM; PMA) enhanced 
peak Ica by -30% (compare Figure 2.5A and Figure 2.6A). In the presence of 
imetit (100 nM), PMA-stimulated Ica was reduced by -45% and this response was 
antagonized by clobenpropit (50 nM) (Figure 2.6A). PMA also elicited a 
concentration-dependent increase in dopamine release: in the 10 nM-1 pM PMA 
concentration range, dopamine release was increased -2-3-fold above control
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Figure 2.5. Panel A: peak calcium currents and normalized peak calcium current, 
evoked in NGF-differentiated PCI2 -H3 by stepping from the holding potential of -40 
mV to the test potential of +10 mV, do not differ from calcium currents evoked in 
PCI2 -H3 cells transfected with the GPy scavenger p-ARKI (PCI2 -H3/P-ARKI). 
Notably, H3R activation with imetit (100 nM) fails to reduce peak calcium current in 
PCI2 -H3/P-ARKI cells. Individual traces are from independent experiments. Bars 
represent means (± SEM; n=20). Panel B: endogenous dopamine release was 
measured in PCI2 -H3/P-ARKI cells in response to K"" (100 mM). Dopamine 
exocytosis was inhibited by nifedipine (5 pM), but not by imetit (100 nM), either alone 
or in combination with clobenpropit (CBP, 50 nM). Bars are means ± S.E.M. (n =20- 
25). Significantly different from alone (*, p<0.05 by AN OVA followed by post hoc 
Dunnett’s test).
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Figure 2.6. Activation of PKC with the phorbol ester PMA (300 nM) increases peak 
calcium current and normalized current in both PCI2 -H3 (Panel A) and PCI2 -H3/P- 
ARK1 cells (Panel B). In PCI2 -H3 cells, incubation with imetit (100 nM) significantly 
reduces peak calcium current, an effect prevented by CBP (50 nM). Notably, the imetit- 
induced calcium current reduction in PCI2 -H3 cells is not present in PCI2 -H3/P-ARKI 
cells. Individual traces are from independent experiments. Bars represent means (± 
SEM; n=20; *, p<0.05 and **, p<0.01 by AN OVA followed by post hoc Dunnett’s test).
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Figure 2.7. Activation of H3R attenuates endogenous dopamine exocytosis elicited by 
PKC activation with PMA (300 nM) in PCI2 -H3 cells but not in PC1 2 -H3/|3-ARK1 cells. 
Panels A and B: concentration-response curves for PMA-induced dopamine release in 
PCI2 -H3 and PCI2 -H3/P-ARKI cells, respectively. Activation of H3R with imetit (100 nM) 
significantly reduced PMA-induced dopamine release in PCI2 -H3 cells (A), an effect that 
was antagonized by CBP (50 nM; panel C). In PC1 2 -H3/(3-ARK1 cells (B), H3R activation 
with imetit (100 nM) failed to affect the PMA-induced dopamine release. Panels C and D 
represent dopamine release elicited by activation of PKC with PMA (300 nM) in the 
absence or presence of imetit (100 nM), either alone or in combination with clobenpropit 
(CBP, 50 nM). Bars are means ± S.E.M. (n = 10 for C and n = 15 for D). Significantly 
different from PMA alone (**, p<0.01 by AN OVA followed by post hoc Dunnett’s test).
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(Figure 2.7A). In the presence of imetit (100 nM) the concentration-response 
curve for PMA was shifted to the right by two orders of magnitude (Figure 2.7A). 
Incubation with clobenpropit (50 nM) antagonized the effect of imetit (Figure 2.7C). 
Application of PMA (300 nM) to PCI2 -H3/P-ARKI cells enhanced peak Ica by 
-30% (Figure 2.6B). Notably, activation of H3R with imetit in PCI2 -H3/P-ARKI cells 
failed to attenuate the PMA-stimulated Ica (Figure 2.6B). Moreover, in PCI2 -H3/P- 
ARK1 cells, H3R activation did not modify PMA-induced dopamine exocytosis 
(Figure. 2.7B). Indeed, the PMA concentration-response curve for the promotion of 
dopamine exocytosis was the same whether in the presence or absence of imetit 
(Figure 2.7B), and the magnitude of the exocytotic response to the 300 nM 
concentration of PMA did not differ from that recorded in the presence of imetit, 
either alone or together with clobenpropit (Figure 2.7D). Thus, stimulation of PKC 
in PCI2 -H3 and PCI2 -H3/P-ARKI cells confirmed that a Gpy-dependent inhibition 
of Ica plays a pivotal role in the anti-exocytotic effect of H3R activation.
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2.9.1 DISCUSSION
The data presented here indicate that Gpy subunits, liberated from Gapy 
trimers upon H3R activation attenuate neuronal Ica and consequent 
neurotransmitter exocytosis. This establishes a novel mechanism of H3R 
transduction capable of preventing excessive NE release, a recognized 
cardioprotective action (Levi et al., 2007).
The PC12 rat pheochromocytoma cell line was utilized in this investigation 
as it acquires a sympathetic nerve phenotype when treated with NGF (Dichter et 
al., 1977). Having stably transfected PCI2 cells with human H3R, a PTX-sensitive 
Gj/o-coupled receptor (see Figures 2.2 and 2.4), it was important to demonstrate - 
using the whole-cell patch clamp technique - the presence of an Ica likely 
responsible for the exocytosis of dopamine, the endogenous transmitter in these 
cells (Chen and Westfall, 1994). Indeed, by stepping to different test potentials in 
the -40 to +40 mV range, a current was identified in PCI2 -H3 cells with typical Ica 
characteristics (i.e., shape of the I A/ curve, its persistence in the absence of Na^ in 
the bathing solution and its sensitivity to 0.1 mM CdCy which was also inhibited by 
the L- and N-type Ca^  ^ channel blockers nifedipine and w-CTX, respectively. 
Moreover, this Ica was amplified by stimulation of adenylyl cyclase with forskolin 
and by PKC activation with a phorbol ester, responses which are typical of 
neuronal Ica (Bean et al., 1984;Yang and Tsien, 1993). Notably, H3R activation 
with the selective agonist imetit (Garbarg et al., 1992) markedly reduced the Ica in 
control and both adenylyl cyclase- or PKC-stimulated conditions, an action 
inhibited by H3R blockade with the selective antagonist clobenpropit (Van der Goot
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et al., 1992). These findings reveal that the decrease in intracellular Ca^  ^ which 
was previously described to occur in response to H3R activation (Silver et al., 
2002;Seyedi et al., 2005) originates from a reduction in Ca^  ^influx via VOCC.
To determine whether the H3R-mediated decrease in Ica is due to inhibition 
of VOCC by the Gj/o-derived Gpy dimer, PCI2-H3 cells were transfected with the 
Gpy scavenger p-ARKI (Koch et al., 1994). H3R activation in PCI2-H3/P-ARKI 
cells failed to inhibit Ica, unequivocally demonstrating the pivotal role played by the 
Gpy dimer in the H3R-mediated inhibition of VOCC. Clearly, the Gpy dimer-induced 
VOCC inhibition is also of major importance for the anti-exocytotic effects of H3R 
activation. Indeed, the imetit-induced inhibition of dopamine exocytosis in PCI2-H3 
cells was prevented not only by a membrane-permeable phosducin-like anti-Py 
peptide (Chang et al., 2000) but also in cells transfected with the Gpy scavenger p- 
ARK1. Moreover, the Gpy scavenger prevented the H3R-mediated attenuation of 
dopamine exocytosis elicited by PKC activation with the phorbol ester PMA.
Interestingly, whereas nifedipine and w-CTX each inhibited Ica, only 
nifedipine attenuated dopamine release. Thus, although both L- and N-type Ca^  ^
channels are present in PCI2 -H3 cells, only the L-type appears to be involved in 
dopamine exocytosis and is Gpy-sensitive. In fact, Ca^ "" entering through the L-type 
channel is the likely stimulus for dopamine release in PCI2 cells (Kanwal et al., 
1997). Furthermore, although the Gpy dimer is generally viewed as an N-type Ca^  ^
channel inhibitor (Ikeda, 1996;Herlitze et al., 1996;Catterall, 2000), a Gpy-induced 
inhibition of the L-type Ca^  ^ channel has also been recognized (Ivanina et al., 
2000). In contrast to dopamine release in PCI 2 cells, both L- and N-type Ca^^
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channels participate in neurotransmitter release from cardiac sympathetic nerve 
endings. Indeed, the H3R agonist imetit synergizes with either nifedipine or w-CTX 
to attenuate NE exocytosis from cardiac synaptosomes (Seyedi et al., 2005).
Expression of the p-ARKI polypeptide failed to modify the H3R-mediated 
attenuation of the forskolin-induced increase in intracellular cAMP and associated 
dopamine exocytosis (see Figure 2.2). Although a py-induced inhibition of adenylyl 
cyclase has been described in insect ovarian cells (Taussig et al., 1993), these 
findings clearly indicate that the Gpy dimer liberated upon H3R activation is not 
responsible for the reduction of adenylyl cyclase activity in differentiated PCI2 -H3 
or PCI2 -H3/P-ARKI cells. Therefore, a direct Py-induced inhibition of Ica at the 
VOCC level is likely to play a key role in the H3R-mediated anti-exocytotic effect. 
The Gpy dimer is also liberated upon PGEa-induced activation of EP3R, another 
Gi/o-coupled receptor with anti-exocytotic properties. PGE2 formation is the final 
step of the MAPK signaling cascade initiated by H3R activation, culminating in the 
attenuation of NE exocytosis from cardiac sympathetic nerve endings (Levi et al., 
2007). This substantiates the present findings on the pivotal role of the Gpy dimer 
as an inhibitor of Ica and consequent exocytosis.
It has previously been reported that the anti-exocytotic effect of H3R 
activation is associated with a decrease in [Ca^^i in SH-SY5Y human 
neuroblastoma cells stably transfected with H3R (Silver et al., 2 0 0 2 ) giving 
foundation to the hypothesis that the decrease in [Ca^^i was due to a Garinduced 
inhibition of adenylyl cyclase, ultimately resulting in a decreased PKA-induced 
phosphorylation of VOCC (Seyedi et al., 2005). The novelty of the present findings
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is that a direct Gpy-induced inhibition of VOCC, resulting in an attenuation of Ica, 
plays a pivotal role in the HsR-mediated decrease in [Ca^^i and associated anti- 
exocytotic effects. Figure 2.8 summarizes the signaling associated with H3R 
activation and the attenuation of Ca^  ^influx into sympathetic nerve endings.
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Figure 2.8. H3 R activation attenuates the influx of Ca^  ^ via VOCC into 
sympathetic nerve endings. Abbreviations; AC, adenylyl cyclase; AA, 
arachidonic acid; COX, cyclooxygenase; MAPK, mitogen-activated protein 
kinase; P, phosphorylation; PGE2, prostaglandin E2; PKA, protein kinase A; 
PKC, protein kinase C; PL, phospholipids; CPLA2 , cytosolic phospholipase A2.
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A FUNCTIONAL LINK BETWEEN SENSORY C-FIBERS, MAST CELLS AND 
SYMPATHETIC NERVES IN THE HEART 
3. INTRODUCTION
3.1 H3R and Sensory Nerves in the Heart
Negative modulation of neurotransmitter release by H3R is not limited to NE 
from sympathetic nerves. The activation of inhibitory pre-junctional H3R inhibits the 
release of various neurotransmitters from adrenergic (Ishikawa and Sperelakis, 
1987;Endou et al., 1994) and cholinergic (Trzeciakowski, 1987) nerve endings. 
H3R activation also produces inhibition of neuropeptide release from sensory 0- 
fibers of the heart (Imamura et al., 1996). Imetit reduced the overflow of calcitonin 
gene-related peptide (CGRP) from sensory nerves in guinea pig heart by 50%, 
supporting previous reports of a functional H3R presence on sensory nerve 
endings in the lung and spleen (Dimitriadou et al., 1994;Delaunois et al., 1995). 
Pretreatment of the lungs with imetit has also been shown to significantly reduce 
the release of Substance P from sensory C-fibers (Nemmar et al., 1999).
Sensory nerves are present throughout autonomic effector systems and 
represent an important physiological component of autonomic control. Orthodromic 
impulses carried by sensory motor nerves convey the sensation of pain in 
response to a physical stimulus, whereas antidromic impulses carried along these 
nerves result in the local release of peptide neurotransmitters. The neuropeptides 
CGRP and Substance P are co-transmitters in many unmyelinated primary 
sensory afferents. In addition to modulation of CGRP release, H3R have been
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shown to negatively modulate the release of Substance P from sensory nerve 
endings in the rat (Ohkubo et al., 1995). The heart is highly innervated with 
sensory nerves containing CGRP and Substance P, indicative of an important role 
of these neuropeptides in this organ. Chemical denervation and selective 
ganglionectomy studies demonstrate that the loss of sympathetic or sensory 
innervations induces significant changes in the remaining nerves (Burnstock, 
2009). Therefore it appears likely that important interactions or cross-talk occur 
between these nerves. Modification of these interactions may disturb homeostasis 
and become significant in pathological conditions. The interactions between 
sensory and sympathetic nerves are not clearly defined and remain to be fully 
elucidated.
3.2 Neuropeptide Signaling in the Heart
CGRP is a 37-amino acid neuropeptide produced by the alternate splicing of the 
calcitonin/CGRP gene (Amara et al., 1982). CGRP is found in abundance in both 
the central and peripheral nervous systems where it serves a signaling function 
(Rosenfeld et al., 1983). CGRP has a wide variety of actions including, 
vasodilation, gastric acid secretion, behavioral effects (modulation of food intake), 
analgesia and regulation of body temperature. CGRP-immunoreactive sensory 
neurons are present in most tissues within blood vessels, non-vascular smooth 
muscle and in the myocardium itself (Lundberg et al., 1992). CGRP is one of the 
most potent vasodilators (Bell and McDermott, 1996) and exerts positive 
chronotropic and inotropic effects upon the heart (Yamaguchi et al., 1988). The
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CGRP receptor is actually a receptor complex formed by combination of the 
calcitonin-like receptor (CLR) which forms the ligand binding site, and a single 
transmembrane domain receptor activity-modifying protein (RAMP1) concerned 
with receptor trafficking and ligand selectivity (McLatchie et al., 1998). Activation of 
the CGRP receptor increases both cAMP production and intracellular Ca^  ^ via 
stimulation of adenylyl cyclase activity (Aiyar et al., 1999). Marked changes occur 
in CGRP plasma concentration in several pathological conditions including 
congestive heart failure (Anand et al., 1991) and acute myocardial infarction (Mair 
et al., 1990) indicating a role for this peptide. A number of potent CGRP receptor 
antagonists have been identified including the peptide fragment and competitive 
antagonist CGRPg-s? (Dennis et al., 1990). CGRP-induced tachycardia is 
prevented by treatment with this antagonist (Kunz et al., 2007).
In sensory nerves, CGRP is stored in large dense cored vesicles together 
with another neuroactive peptide. Substance P (Gibbins et al., 1985). Significant 
amounts of Substance P are present in human (Reinecke et al., 1980) and cavian 
hearts (Urban and Papka, 1985), with Substance P immunoreactivity detected in 
coronary vessels, cardiac ganglion cells and in the myocardium. Substance P 
belongs to a family of structurally related tachykinin peptides that include NKA, 
NKB and the NKA-derived peptides neuropeptide K and neuropeptide y (Helke et 
al., 1990). Three pharmacologically distinct neurokinin receptors designated NK-1, 
NK-2 and NK-3 have been characterized based on the relative potency of 
tachykinin agonists. Substance P preferentially binds to the NK-1 receptor, NKA to 
the NK-2 receptor and NKB with NK-3 receptor. NK-1 receptors in the CNS,
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smooth muscle and endothelial cells mediate vasodilation and increase vascular 
permeability in response to Substance P (Lundberg et al., 1984). Binding sites for 
Substance P have also been identified on cells that participate in the immune 
response including lymphocytes, macrophages and mast cells (Piotrowski et al., 
1984). Specific non-peptide antagonists of the NK-1 receptor have been described 
including CP99994 (McLean et al., 1993). Substance P has been linked to post- 
ischemic myocardial dysfunction. Indeed, NK-1 antagonists are effective in 
reducing post-ischemic myocardial dysfunction (Chiao and Caldwell, 1996).
3.3 The Release of Neuropeptides from Sensory C-Fibers 
A variety of stimuli induce the release of neuropeptides from sensory C-fibers, 
including capsaicin (the active component of chili peppers), antidromic nerve 
stimulation and ischemia (Lundberg et al., 1992). Notably, Substance P, 
neurokinin A and CGRP can be released from sensory nerves simultaneously by 
these stimuli (Franco-Cereceda, 1988). Moreover, CGRP and Substance P are 
released from the heart in response to capsaicin treatment (Hoover, 1987). 
Capsaicin belongs to the family of capsaicinoids which also includes 
dihydrocapsaicin and nordihydrocapsaicin. Acute capsaicin administration induces 
positive chronotropic and inotropic effects (Franco-Cereceda and Lundberg, 1985) 
similar to those seen with the in vitro administration of CGRP. Interestingly, high- 
dose capsaicin treatment can deplete cardiac C-fiber peptide stores. In fact, high- 
dose capsaicin exposure can reduce Substance P immunoreactivity by greater
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than 90% (Papka and Urban, 1987), proving that Substance P in the heart is 
largely located in these capsaicin-sensitive afferents.
Capsaicin interacts with the transient receptor potential vanilloid 1 (TRPV1) 
receptor (Helliwell et al., 1998). TRPV1 is a cation-selective channel expressed in 
sensory C- and A-fibers (Gunthorpe et al., 2002). Activation of TRPV1 results in 
the significant accumulation of intracellular Ca^ .^ TRPV1 can be activated by 
physical and chemical stimuli including noxious heat and protons (Rang et al., 
1991;Cesare et al., 1999). TRPV1 are associated with both positive and negative 
effects on cardiac function. During myocardial ischemia, ischemic metabolites act 
via TRPV1 on sensory nerves to induce chest pain (Numazaki et al., 2002). 
However, the stimulation of endogenous CGRP release via TRPV1 activation is 
thought to provide cardioprotection in the ischemic heart (Hu et al., 2002). N- 
oleoyldopamine an endogenous capsaicin-like lipid has also been shown to protect 
the heart against ischemia-induced injury via TRPV1 activation on sensory nerves 
(Zhong and Wang, 2008). Interestingly, TRPV1 knockout mice demonstrate 
impaired ischemic preconditioning and reduced protection against myocardial 
injury (Wang and Wang, 2005). However, incubation of the cardiac synaptosomal 
fractions containing both sensory and sympathetic nerve endings with capsaicin 
increases the release of endogenous NE (Seyedi et al., 1999). In this study, this 
effect was inhibited by the TRPV1 antagonist capsazepine. In addition, excessive 
capsaicin ingestion has been linked to arterial hypertensive crises in humans 
(Patane et al., 2009) presumably acting via TRPV1.
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3.4 Sensory C-Fibers and Myocardial ischemia
Stimulation of cardiac sensory C-fiber results in the release of CGRP and 
Substance P (Maggi, 1995). Moderate acidosis and stop-flow ischemia have also 
been shown to increase neuropeptide release from sensory nerves (Franco- 
Cereceda and Liska, 2000). Low pH and high are both associated with 
myocardial ischemia and are known to contribute to the release of neuropeptides 
(Mair et al., 1990). Indeed, the release of CGRP is potentiated during ischemia in 
the isolated guinea pig heart (Franco-Cereceda et al., 1989) and Substance P 
release is also known to be increased in ischemia (Arreola et al., 2004). The 
increases in neuropeptide release may be associated with the accumulation of 
ROS and elevated intracellular Ca^  ^ that occur under ischemic conditions. It has 
previously been shown that ROS derived from hydrogen peroxide, 
xanthine/xanthine oxidase mixture, or produced endogenously at reperfusion 
following prolonged ischemia, activate afferent sensory C-fibers (Stahl et al., 
1993;Ustinova and Schultz, 1994;Huang et al., 1995). The major ROS that may be 
responsible for the increased release of neuropeptides in ischemic conditions are 
the superoxide anion radical, hydrogen peroxide and the hydroxyl radical. The 
superoxide anion radical can dismutate to form hydrogen peroxide, which in the 
presence of iron can further react to form the hydroxyl radical via the Fenton 
reaction (Comhair and Erzurum, 2002).
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3.5 A Cardioprotective Role for Neuropeptides
Some evidence supports a beneficial role for peptides released from sensory C- 
fibers in myocardial ischemia/reperfusion (Kallner and Franco-Cereceda, 1998). In 
this study, neuropeptide-depleted pigs displayed less severe myocardial infarction 
when subjected to ischemia. In support of these findings the mean arterial blood 
pressure of neuropeptide-depleted pigs has been shown to be significantly 
increased (Deng and Li, 2005). Moreover, CGRP is thought to be integral to the 
beneficial effects of ischemic preconditioning. The cardioprotection afforded by 
ischemic preconditioning has been attributed to the stimulation of endogenous 
CGRP release. Capsaicin induced release of CGRP or pretreatment with 
exogenous CGRP has been shown to protect the myocardium from injury, reduce 
cardiac dysfunction and ventricular arrhythmia (Li et al., 1996). CGRP has also 
been shown to be protective in cardiac anaphylaxis (Dai et al., 2000). Indeed, 
perfusion of guinea pig hearts with CGRP accelerated the recovery of effective 
cardiac function and shortened the duration and incidence of atrioventricular block 
following treatment with antigen. Most noteworthy, the use of capsaicin skin 
patches has been shown to raise ischemic thresholds and prolong exercise time in 
patients with stable coronary disease (Fragasso et al., 2004).
3.6 Neuropeptides and Cardiac Mast Cells
Although some evidence leans towards a cardioprotective role for neuropeptides in 
the heart, an important potential relationship between sensory nerves and 
inflammatory mast cells should not be overlooked. Neuropeptide expression has
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been demonstrated in nerve fibers closely associated with mast cells in various 
tissues (Stead et al., 1990;Alving et al., 1991). Mast cells and sensory C-fibers 
also appear to closely interact in the heart (Williams et al., 1995). Furthermore, 
both CGRP and Substance P induce mast cell degranulation (Benyon et al., 1987). 
Once activated, mast cells release a host of predominantly deleterious mediators 
(histamine, TNFa, IL-6 , platelet activating factor, ROS etc.). The release of these 
mediators can initiate an inflammatory cascade with the potential to impair 
myocardial contractile function, tissue stability and electrophysiological activity. 
Interestingly, histamine can be cardioprotective via activation of H3R on 
sympathetic nerve endings which attenuates NE release in myocardial ischemia 
(Seyedi et al., 2005), However, histamine also exhibits arrhythmogenic properties 
which are mediated by HiR and H2R (Wolff and Levi, 1986).
The activation of mast cells by neuropeptides has been clearly established. 
Indeed, CGRP is a potent histamine-releasing agent (Foreman, 1993) and 
Substance P has also been demonstrated to release histamine from human mast 
cells (Louis and Radermecker, 1990;Cross et al., 1996). Mast cells are present in 
the myocardium of rodents (Ghanem et al., 1988), canines (Frangogiannis et al., 
1999), and humans (Forman et al., 1985;Dvorak, 1986;Marone et al., 1995). In the 
heart, mast cells generally reside in the interstitial space between myocytes and 
are closely associated with nerves (Silver et al., 2004). The presence and location 
of mast cells in the heart combined with their accumulation in pathological 
conditions have implicated them in the development of myocardial dysfunction 
(Frangogiannis et al., 1999). Notably, mast cell density is significantly increased in
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heart failure (Patella et al., 1998;Chester, 2002). Unveiling a functional link 
between cardiac mast cells and neuropeptides released from sensory nerves in 
the heart may prove to be essential in understanding the important roles these 
neuropeptides play in the heart.
3.7 Mast Cell Renin and a Local Cardiac RAS
At the center of mast cells detrimental contribution to cardiac function is the 
discovery that mast cells contain renin and that the release of this protease 
activates a local cardiac RAS (Silver et al., 2004). The finding that mast cells are a 
novel source of active renin was based on immunohistochemical evidence in intact 
rodent heart (Silver et al., 2004) and was strengthened by the demonstration that 
mast cells synthesize renin protein (Silver et al., 2004;Mackins et al., 2006). 
Traditionally the renin-angiotensin system was thought to be dependent on renin 
derived from renal juxtaglomerular cells. However, using both polyclonal and 
monoclonal anti-renin antibodies, cardiac mast cells in rodents were found to be 
immuno-positive for renin. These findings were substantiated in the human 
mastocytoma cell line, HMC-1 (Silver et al., 2004). Once released into the 
circulation, kidney-derived renin cleaves liver-derived angiotensinogen to form 
AN G I, an inactive decapeptide. AN G I is converted to the biologically active 
product AN G II by ACE, located on the luminal side of the vascular endothelium. 
Circulating AN G II regulates blood pressure, plasma volume and sympathetic 
neural activity (Peach, 1977;Campbell, 1987). The notion of a local tissue-specific 
RAS, in addition to the classic circulating RAS (Peach, 1977;Campbell, 1987),
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remains controversial and is subject to some speculation (Danser, 2003;Bader, 
2002;Campbell, 2008). Despite the controversy, all the necessary components of 
RAS have been identified in cardiac tissue (Dostal and Baker, 1999;Vane, 
2000;Bader et al., 2001;Silver et al., 2004). The local concentrations of ANG II in 
the heart may exceed those of plasma and therefore play a significant role in 
cardiac function (Dzau, 1987) and in pathophysiological conditions, such as 
myocardial hypertrophy and infarction (Berry et al., 2001b;Gavras and Brunner, 
2001). Crucially, local ANG II production is elevated in the ischemic myocardium 
(Jalowy et al., 1999),
Mast cell-derived renin is important in myocardial ischemia/reperfusion, a 
condition in which both mast cells and ANG II are known to be involved (Kruger et 
al., 1990;lhara et al., 2000). Experiments in Langendorff-perfused guinea-pig and 
mouse hearts subjected to ischemia/reperfusion reveal the pivotal role played by 
renin released from mast cells and subsequent local ANG II formation in the 
development of cardiac arrhythmias. In isolated hearts subjected to myocardial 
ischemia/reperfusion, mast cells degranulate and release renin which converts 
angiotensinogen to ANG I, followed by the generation of ANG II via local ACE. 
ANG II activates ATi-receptors located on the membrane of cardiac sympathetic 
nerve endings, promoting the exocytotic and/or carrier-mediated release of NE 
(Mackins et al., 2006). The excessive release of NE is responsible for the induction 
of reperfusion arrhythmias (such as ventricular tachycardia and ventricular 
fibrillation), which can be prevented by mast cell stabilization, renin inhibition or 
ATi-receptor blockade (Mackins et al., 2006). Notably, these arrhythmias do not
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occur in hearts isolated from mast-cell deficient animals (Mackins et al., 2006). In 
addition to facilitating the release of NE and amplifying its arrhythmogenic effects, 
ANG II can also directly elicit cardiac arrhythmias without a contribution to 
sympathetic hyperactivity (Curtis et al., 1993;Gondo et al., 2001;lravanian and 
Dudley, Jr., 2008).
3.8 A Functional Link Between Sensory Nerves and Mast Cells
Interactions between sensory C-fibers, mast cells and sympathetic nerves 
may be significant in ischemia/reperfusion. This interaction may well contribute to 
the activation of mast cells and the release of renin. The subsequent activation of a 
local cardiac RAS would promote cardiac dysfunction, arrhythmia and sudden 
cardiac death. Despite findings that the exogenous application of CGRP to rat 
heart does not result in significant changes in NE release (Burgdorf et al., 2005) 
there is still a strong possibility of an interaction between sensory and sympathetic 
nerves owing to their close proximity to each other and to cardiac mast cells. The 
neuropeptides CGRP and Substance P once released from sensory nerves in 
ischemia/reperfusion may interact with cardiac mast cells and promote 
hyperactivity of the sympathetic nervous system. Indeed, during 
ischemia/reperfusion the activation of a local cardiac RAS has a significant 
detrimental effect on cardiac function. Mast cells are known to play a pro- 
arrhythmic role in ischemia, with histamine acting at HiR and HzR and renin 
leading to angiotensin II formation being the main culprits of adverse 
electrophysiological activity (Mackins et al., 2006). Notably, treatment with
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disodium chromogiycate (a mast cell stabilizer) prior to or during ischemia is 
effective in reducing the incidence and severity of reperfusion arrhythmias in the 
rat (Walsh et al., 2009).
The relationship between sensory nerves and mast cells is already 
considered pivotal to the development of neurogenic inflammation (Hu et al., 
2008;Jarvikallio et al., 2003). Neuropeptides capable of activating mast cells 
released under ischemic conditions could have a significant bearing on the 
progression of cardiac dysfunction due to local cardiac RAS activation. 
Accordingly, it is important to determine whether a functional link exists between 
sensory C-fibers and cardiac mast cells in myocardial ischemia, whereby 
Substance P and CGRP released from sensory nerves evoke the release of renin 
from mast cell, thus activating a local cardiac RAS.
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3.9 AIM 2
During myocardial ischemia, renin is released from mast cells and activates 
a local cardiac RAS, culminating in the excessive release of NE from sympathetic 
nerves resulting in cardiac dysfunction. Sensory C-fibers contain peptides capable 
of activating mast cells (CGRP and Substance P) and these afferents are present 
in close proximity to these cells in the heart.
Hvpothesis: A functional link exists between sensory C-fibers and cardiac mast 
cells in myocardial ischemia. Substance P and CGRP released from sensory 
nerves evoke the release of renin from mast cells and activate a local cardiac 
RAS. Since the activation of a local RAS is detrimental to cardiac function, 
validation of this hypothesis will unveil an important link between sensory C-fibers 
and mast cells in myocardial ischemia and may yield new therapeutic approaches 
to cardiovascular diseases characterized by hyperadrenergic activity.
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3.9.1 MATERIALS AND METHODS
Cell Culture
The human mastocytoma cell line, HMC-1, was maintained in Iscove’s 
modified Dulbecco’s media supplemented with 25 mM HEPES, 2 mM L-glutamine, 
10 % FBS, 50 U/ml penicillin, 50 pg/ml streptomycin and 1.2 mM monothioglycerol 
at 37"C, 5% CO2 .
IS-hexosaminidase Assay
Pooled confluent flasks of HMC-1 cells were pelleted and resuspended in 
Ringers solution containing (mM) NaCI, 140; KCI, 5; Hepes, 10; MgCL, 1; glucose, 
2; CaCl2 , 2; pH 7.4. HMC-1 samples were incubated with increasing 
concentrations of CGRP or Substance P accordingly for 30 min at 37°C. Samples 
were then pelleted by centrifugation at 2000 x g for 5 min at 4°C. 13-
hexosaminidase levels were assayed using a modification of the method of a 
previously established method (Schwartz et al., 1979). Firstly, to measure the 13- 
hexosaminidase in the releasate, 20 pi of the HMC-1 sample supernatant were 
placed in a well of a 96-well plate with 50 pi of substrate solution (p-nitrophenyl-N- 
acetyl-(3-D-glucosaminide, 1.3 mg/ml in 0.1 M citrate buffer, pH 4.5) and incubated 
for 90 min at 37°C. The reaction was stopped by adding 150 pi of 0.2 M glycine 
(pH 10.7). The optical density was read using a plate reader at 405 nM and 
SoftMax Pro 4.8. To measure the total amount of (3-hexosaminidase, the samples 
were lysed with IX  lysis buffer for 15 min. The samples were then centrifuged at
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14,000 rpm for 10 min at 4°C and 20 pi of the supernatant removed and treated as 
described for the releasate supernatant.
Perfusion of Guinea-Pig Hearts Ex Vivo.
All experiments were approved by the Institutional Animal Care and Use 
Committee of Weill Medical College of Cornell University. 7-8 week old male 
guinea pigs (Charles River Laboratories) weighing 300-350 g were anaesthetized 
with CO2 and euthanized by rapid exsanguination. Hearts were quickly excised 
and perfused with oxygenated Na^ Ringer's solution at 37°C at a constant 
pressure (40 mmH20) via an aortic cannula. The spontaneously beating hearts 
were perfused with Ringer’s solution for 30 min prior to perfusion with capsaicin, or 
the induction of ischemia in a Langendorff apparatus (Radnoti Glass Technology). 
In some cases, hearts were continuously perfused with pharmacological agents 
prior to and during perfusion with capsaicin (CGRPg-s?, CP99994, cromolyn, 
EXP3174 and imetit) or induction of ischemia/reperfusion (CGRPg-s? and 
CP99994). Normothermic global ischemia was induced by complete cessation of 
coronary perfusion for 20 min, followed by 30 min of reperfusion. Coronary flow 
was measured by timed collections of the effluent every 2 min and all samples 
assayed for renin, NE, CGRP and Substance P. Surface electrocardiogram (ECG) 
was obtained from leads attached to the left ventricle and the right atrium and 
analyzed using PowerLab/8SP (ADInstruments).
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NE Assay
Coronary effluent was assayed for NE by HPLC with electrochemical 
detection as previously described (Seyedi et al., 2005). The detection limit was 
approximately 0.2 pmol.
Renin Assay
Coronary effluent was immediately concentrated 8-fold by centrifugal 
filtration (Millipore). Concentrated samples were incubated for 18 hr with human 
angiotensinogen (Calbiochem) 240 nM. Renin activity was determined by 
Gammacoat Plasma Renin Activity ^^ 1^ Radioimmunoassay (Diasorin). The 
detection limit was approximately 0.01 pmol.
CGRP and Substance P Assays
Coronary effluent samples were stored at -20°C for a short period of time 
(i.e.<2 weeks). The samples were then thawed and assayed for CGRP or 
Substance P content with the use of two commercially available enzyme 
immunoassay (EIA) kits according to the manufacturers protocols (rat CGRP kit 
from Cayman Chemical, Inc and Substance P kit from Assay Designs, Inc). The 
detection limits of the kits were 1 pg/ml and 9.76 pg/ml for CGRP and Substance 
P, respectively.
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Reagents
The following reagents were used: human angiotensinogen purchased from 
Calbiochem; capsaicin and cromolyn purchased from Sigma Aldrich; CP99994 (a 
gift from Pfizer); CGRPg-s? and substance P purchased from Anaspec; EXP3174 (a 
gift from Merck, Sharpe and Dohme); imetit purchased from Tocris Bioscience.
Statistics
One-way AN OVA test followed by Dunnett’s procedure was used where 
appropriate and as indicated in the figure legends. p<0.05 was considered 
significant.
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3.9.2 RESULTS
Chemical stimulation of sensory C-fibers with capsaicin in spontaneously 
beating guinea-pig hearts ex vivo elicited the release of the neuropeptides CGRP 
and Substance P. During the first 2 min of capsaicin perfusion (100 nM), the 
overflow of CGRP and Substance P increased ~3 and ~10-fold, respectively 
(Figure 3.1 A and B). The release of these peptides was accompanied by a -3-fold 
increase in the overflow of renin and NE (Figure 3.2A and B).
Perfusion of guinea-pig hearts with the mast cell stabilizer cromolyn (300 
pM) attenuated the capsaicin-induced increase in renin and NE overflow by -65% 
(Figure 3.2A and B), indicating that mast cells were the source of renin released 
into the coronary effluent of hearts perfused with capsaicin and suggesting that NE 
release was secondary to the release of mast cell renin. Notably, when HMC-1 
mast cells in culture were incubated with CGRP (0.1-10 pM) or Substance P (10- 
100 nM) this resulted in a concentration-dependent release of p-hexosaminidase, 
an index of mast cell degranulation (Figure 3.3A and B). In contrast, incubation of 
HMC-1 cells with capsaicin (30 nM-1 pM) failed to elicit significant changes in p- 
hexosaminidase release when compared with control (% release: control, 4.36 ± 
1.20; 1 pM, 5.24 ± 1.79; n=4), indicating that capsaicin did not directly degranulate 
mast cells. Rather, capsaicin enhanced renin overflow into the coronary effluent by 
releasing mast cell-degranulating neuropeptides from sensory C-fibers.
Perfusion of guinea-pig hearts with the specific Substance P receptor 
antagonist CP99994 (100 nM) or with the specific CGRP receptor antagonist 
CGRP8-37 (100 nM) prevented the increases in renin and NE overflows elicited by
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Figure 3.1. Chemical stimuiation of sensory C-fibers with capsaicin elicits 
the release of CGRP and Substance P in isolated guinea-pig hearts. Bars 
(means ± SEM) represent overflows of CGRP and Substance P into the 
coronary effluent. Capsaicin (100 nM, n=6) was perfused for 6 min and the 
coronary effluent was collected at 2 min intervals. Control bars (means ± SEM; 
n=6) represent the basal release of CGRP and Substance P before perfusion 
with capsaicin. *p<0.05, **p<0.01, from control by one-way AN OVA followed by 
Dunnett’s post-test analysis.
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Figure 3.2. Chemical stimulation of sensory C-fibers with capsaicin elicits release 
of mast ceil renin, ANG II formation and NE release in isolated guinea-pig hearts.
Bars (means ± SEM) represent overflows of renin (absolute values of angiotensin I 
formed) and NE (per cent increase above control) into the coronary effluent. Capsaicin 
(100 nM, n=8) was perfused for 8 min alone or in the presence of the mast cell stabilizer 
cromolyn (300 pM, n=5), the substance P NK-1 receptor antagonist CP99994 (Anti-SP; 
100 nM, n=5), the CGRP receptor antagonist CGRPg-s? (Anti-CGRP; 100 nM, n=3), the 
Hs-receptor agonist imetit (100 nM, n=6) or the ANG II ATi-receptor antagonist EXP3174 
(10 nM, n=4). Control bars (means ± SEM; n=34) represent the basal release of renin 
and NE (2.11 pg/hr/g and 0.69 pmol/g, taken as 100%) before perfusion with capsaicin. 
*p<0.05, **p<0.01, from capsaicin alone by one-way AN OVA followed by Dunnett’s post­
test analysis.
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Figure 3.3. Degranuiation of the human mastocytoma cell line (HMC-1) 
with CGRP and Substance P. Incubation of HMC-1 cells with CGRP or 
Substance P for 20 min elicits p-hexosaminidase release (an index of mast 
cell degranulation) in a concentration-dependent manner. Points are means (± 
SEM; n=5-10) of percent increases in CGRP and Substance P release above 
basal level (% release; 3.78 ± 0.18 and 2.11 ± 0.22; n=6-9). *p<0.05, 
**p<0.01, from basal by one-way ANOVA followed by Dunnett’s post-test 
analysis.
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capsaicin (Figure 3.2A and B). This suggested that Substance P and CGRP 
released from sensory C-fibers by chemical stimulation with capsaicin activated 
NK-1 and CGRP receptors on mast cells, eliciting their degranulation and the 
release of renin, followed by the downstream release of NE from sympathetic 
nerves.
Perfusion of guinea-pig hearts with the selective H3R agonist imetit (100 
nM) prevented the capsaicin-induced increase in renin and NE overflow into the 
coronary effluent (Figure 3.2A and B). This suggested that the activation of 
negatively modulatory H3R, which are known to be expressed on sensory C-fibers 
(Imamura et al., 1996), diminished the release of mast cell renin by attenuating the 
release of neuropeptides from sensory nerves and the subsequent downstream 
release of NE from sympathetic nerves.
In contrast, perfusion of guinea-pig hearts with the selective ATi-receptor 
antagonist EXP3174 (10 nM), prevented only the capsaicin-induced increase in 
NE overflow, but not that of renin (Figure 3.2A and B). This suggested that while 
capsaicin still elicited the neuropeptide-induced release of mast cell renin, and the 
consequent activation of a local RAS culminating in ANG II formation, NE failed to 
be released from sympathetic nerves due to blockade of neuronal ATi-receptors.
ROS overload during ischemia/reperfusion is known to provoke the release 
of neuropeptides from sensory nerves (Stahl et al., 1993;Ustinova and Schultz, 
1994;Huang et al., 1995). Hence, I next investigated the coronary overflow of 
CGRP, Substance P, renin and NE from isolated guinea-pig hearts subjected to 20 
min global ischemia followed by 30 min reperfusion. During the
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Figure 3.4. CGRP and Substance P are released from isolated guinea-pig 
hearts subjected to ischemia/reperfusion. Bars (means ± SEM) represent 
overflows of CGRP and Substance P into the coronary effluent of isolated 
guinea-pig hearts. Hearts were subjected to ischemia/reperfusion (l/R) (i.e., 20- 
min global ischemia (Isch) and 30-min reperfusion; n= 6). Control bars (Pre; 
means ± SEM; n=6) represent basal release of CGRP and Substance P 
preceding l/R. *p<0.05, **p<0.01, from Pre by one-way ANOVA followed by 
Dunnett’s post-test analysis.
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Figure 3.5. Combined CGRP and SP receptor blockade exerts 
cardioprotective, anti-RAS effects in isolated guinea-pig hearts subjected to 
ischemia/reperfusion. Coronary overflow of renin and NE, and duration of 
reperfusion arrhythmias (VTA/F) in isolated guinea-pig hearts subjected to 
ischemia/reperfusion (l/R) (i.e., 20-min global ischemia and 30-min reperfusion; 
n=6). Other hearts were subjected to l/R preceded by 10-min perfusion with both 
CGRP and SP NK-1 receptor antagonists (i.e., CGRPg-sy, 100 nM, and CP99994, 
100 nM, respectively) (n=4). Both antagonists remained present throughout the 
period of reperfusion. Bars are means (± SEM) of overflows during the first 6 min of 
reperfusion and duration of VT/VF. * and **: p<0.05 and p<0.01, respectively, from 
l/R control by ANOVA followed by Dunnett’s multiple comparisons test.
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Figure 3.6. CGRP and Substance P receptor antagonists fail to affect the 
release of CGRP and Substance P elicited by ischemia/reperfusion in isoiated 
guinea-pig hearts. Bars (means ± SEM) represent overflows of CGRP and 
Substance P into the coronary effluent of isolated guinea-pig hearts. Hearts were 
perfused with both CGRPs-s? (100 nM) and CP99994 (100 nM) for 10 min 
preceding ischemia/reperfusion (l/R) (i.e., 20-min global ischemia and 30-min 
reperfusion; n= 6). The antagonists remained present throughout reperfusion. 
Control bars (means ± SEM; n=6) represent basal release of CGRP and Substance 
P preceding l/R. *p<0.05, **p<0.01, from control by one-way ANOVA followed by 
Dunnett’s post-test analysis.
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initial 2 min of reperfusion the overflow of CGRP and Substance P increased ~8 
and 10-fold above pre-ischemic control, respectively (Figure 3.4A and B). 
Furthermore, the overflows of renin and NE also increased during reperfusion, -10 
and -75-fold, respectively (Figure 3.5B and C). Severe arrhythmias, such as 
ventricular tachycardia (VT) and VF invariably occurred during reperfusion. Their 
incidence was 100% and their duration was -500 seconds. Isolated guinea-pig 
hearts were then perfused with the CGRP and Substance P receptor antagonists 
CGRP8-37 (100 nM) and CP99994 (100 nM) in combination and then subjected to 
ischemia/reperfusion. In the presence of the neuropeptide receptor antagonists, 
the increases in the overflows of Substance P and CGRP were as large as in their 
absence (Figure 3.6A and B). In contrast, renin and NE overflows were reduced by 
-70 and -50%, respectively, and there was also a -70% decrease in the duration 
of VTA/F (Figure 3.5A, B and C). These findings suggested that CGRP and 
Substance P released from sensory C-fibers during ischemia/reperfusion elicit the 
release of renin from mast cells, contributing to the activation of a local cardiac 
RAS culminating in the formation of ANG II, NE release and the generation of 
reperfusion arrhythmias.
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3.9.3 DISCUSSION
These results identify an important interaction between sensory C-fibers 
and cardiac mast cells in ischemia/reperfusion, causing the activation of a local 
RAS and culminating in severe arrhythmic dysfunction. Chemical stimulation of 
sensory C-fibers with capsaicin induces the release of CGRP and Substance P 
(see Figure 3.1 A and B). These increases in CGRP and Substance P coincide with 
an increased overflow of renin and NE (see Figure 3.2A and B). It has previously 
been demonstrated that renin derived from mast cells is capable of initiating the 
formation of ANG II which elicits NE release from cardiac sympathetic nerves 
(Mackins et al., 2006). Furthermore, CGRP and Substance P are known to 
activate mast cells (Louis and Radermecker, 1990;Foreman, 1993;Cross et al., 
1996). Indeed, both CGRP and Substance P caused degranulation of human mast 
cells in culture (HMC-1 cells) in a concentration-dependent manner (see Figure 
3.3A and B). Notably, the increased overflow of renin and NE in capsaicin-treated 
hearts was prevented by the mast cell stabilizer, cromolyn. These findings confirm 
that cardiac mast cells are the source of renin, released during capsaicin 
perfusion.
The increases in renin and NE overflow associated with capsaicin treatment 
were attenuated by CGRPg-sz, a CGRP antagonist and CP99994, a Substance P 
antagonist (see Figure 3.2A and B). Hence, CGRP and Substance P contribute to 
the release of renin from mast cells via activation of CGRP and NK-1 receptors, 
respectively. Activation of H3R on sympathetic nerves has been shown to 
attenuate the release of NE by reducing Ca^ "^  influx into nerve terminals via a direct
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action on VOCC (Morrey et al., 2008), by an inhibition of adenylyl cyclase via Goi 
(Seyedi et al., 2005) and by induction of MARK activity resulting in reduced 
phosphorylation of VOCC (Levi et al., 2007). H3R are also present on sensory C- 
fibers where their activation has been shown to attenuate the release of 
neuropeptides (Imamura et al., 1996). The H3R agonist imetit reduced both renin 
and NE overflow of capsaicin-treated hearts (see Figure 3.2A and B). These 
findings presumably stem from an H3R-mediated attenuation of neuropeptide 
release from sensory C-fibers, thus reducing cardiac mast cell degranulation and 
the release of renin. In addition, a direct inhibition of NE release from sympathetic 
nerves via activation of H3R present on the sympathetic terminals in the heart may 
also contribute to this attenuation of renin and NE overflow.
ATi-receptors are located in close proximity to cardiac mast cells on 
sympathetic nerves (Reid et al., 2004). A consequence of local RAS activation is 
ANG II generation. Activation of ATi-receptors promotes NE release and 
arrhythmic dysfunction. Crucially, perfusion of capsaicin-treated hearts with 
EXP3174, an ATi-receptor antagonist, produced a significant attenuation of NE 
overflow, whilst renin overflow was not modified. This finding supports the notion 
that CGRP and Substance P released from sensory C-fibers activate mast cells, 
releasing renin into the interstitium. The activation of a local RAS leads to the 
generation of ANG II and the promotion of NE release via activation of ATi- 
receptors on sympathetic nerves. Additionally, it is also important to consider that 
ANG II can cause arrhythmic dysfunction via a direct action on the heart (De Mello, 
2001;Harada et al., 1998).
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ROS overload during ischemia/reperfusion is also capable of eliciting 
neuropeptide release from sensory nerves (Stahl et al., 1993;Ustinova and 
Schultz, 1994;Huang et al., 1995). Having established that chemical stimulation of 
sensory C-fibers elicits the release of CGRP and Substance P together with the 
knowledge that ROS also have the ability to release these peptides from sensory 
nerves, the next logical step was to examine the effects of ischemia/reperfusion on 
the overflow of CGRP, Substance P, renin and NE into the coronary effluent of 
guinea pig hearts ex wVo. The overflow of CGRP and Substance P was markedly 
increased during reperfusion following a period of ischemia (see Figure 3.4A and 
B). This provided evidence that ROS overload during ischemia evoke the release 
of neuropeptides from sensory C-fibers in the guinea-pig heart model. The surge in 
overflow of these peptides was accompanied by an increased overflow of renin 
and NE (see Figure 3.5B and C). These findings suggest that ischemia/reperfusion 
as well as chemical stimulation of sensory C-fibers with capsaicin cause the 
activation of a local cardiac RAS culminating in an exaggerated release of NE from 
sympathetic nerves. Guinea-pig hearts subjected to ischemia/reperfusion 
underwent a period of arrhythmia characterized by ventricular tachycardia and 
ventricular fibrillation (VTA/F) as detailed in Figure 3.5A (Inset). Activation of a 
local cardiac RAS is associated with reperfusion arrhythmias, and previous studies 
have demonstrated that mast cell renin release and subsequent ANG II generation 
contribute to these rhythm disturbances (Mackins et al., 2006). Blockade of CGRP 
and NK-1 receptors with the specific antagonists CGRPs-sz and CP99994 
attenuated the overflow of both renin and NE, and also decreased the duration of
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VTA/F in hearts subjected to ischemia/reperfusion (see Figure 3.5A, B and C). 
These findings indicate that CGRP and Substance P initiate the activation of a 
local cardiac RAS, and provide evidence for the presence of an important link 
between sensory C-fibers, mast cells and sympathetic nerves in 
ischemia/reperfusion. ROS may also activate mast cells and sympathetic nerves 
directly and would therefore be capable of promoting both renin and NE release 
independent of the neuropeptides released from sensory C-fibers. Importantly, the 
overflow of CGRP and Substance P from hearts subjected to ischemia/reperfusion 
in the presence of the neuropeptide antagonists remained elevated with respect to 
control (see Figure 3.6A and B). These data reaffirm that CGRP and Substance P 
released from C-fibers play an important role in the increased overflow of renin and 
NE that occurred during ischemia/reperfusion. Furthermore, these data clearly 
indicate that the antagonism of CGRP and NK-1 receptors present on mast cells 
were responsible for the attenuation of renin and NE overflow and VT/VF duration 
recorded in the presence of the specific CGRP and Substance P antagonists.
In summary, the data presented here support the hypothesis that sensory 
C-fibers and cardiac mast cells interact in ischemia/reperfusion, causing the 
activation of a local RAS which culminates in severe arrhythmic dysfunction. The 
interaction between nerves and mast cells in capsaicin treated conditions and in 
ischemia/reperfusion are illustrated in Figure 3.7. Based on these findings it is 
possible to postulate that an overload of ROS during ischemia elicits the release of 
the neuropeptides CGRP and Substance P from sensory C fibers; these peptides 
then activate cardiac mast cells to release renin. Once released, renin activates a
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local cardiac RAS which ultimately generates ANG II. ANG II interacts with ATi- 
receptors present on sympathetic nerves and promotes the release of NE, thus 
inducing arrhythmias and potentially leading to sudden cardiac death.
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Figure 3.7. Proposed functional link between sensory C-fibers and cardiac mast 
cells, and its role in renin release and local RAS activation. (A) Chemical stimulation 
of cardiac sensory C-fibers with capsaicin elicits the release of neuropeptides (CGRP and 
Substance P) which activate their respective receptors on cardiac mast cells, sequentially 
promoting their degranulation, renin release, RAS activation, angiotensin II formation, 
stimulation of ATrreceptors on sympathetic nerves and thus, NE release. (B) Reactive 
oxygen species (ROS) generated during ischemia/reperfusion act upon: sensory C-fibers, 
eliciting the release of neuropeptides; cardiac mast cells, evoking the release of renin; and 
sympathetic nerves, promoting the release of NE, leading to the generation of arrhythmias 
and sudden cardiac death.
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4. GENERAL DISCUSSION
The research presented in Chapter 2 and Chapter 3 of this thesis is linked 
by the common thread that H3R activation attenuates both NE release from 
sympathetic nerve endings (Imamura et al., 1994) and neuropeptide release from 
sensory C-fibers in myocardial ischemia (Imamura et al., 1996). It is also likely that 
HsR-mediated attenuation of the release of both NE from sympathetic nerves and 
neuropeptides from sensory C-fibers involve a pertussis toxin-sensitive G i/o protein 
and are associated with decreased influx of Ca^  ^ through VOCC (Endou et al., 
1994;Morrey et al., 2008).
Chapter 2 of this thesis addresses the role of the G(By subunit in HsR- 
mediated attenuation of neuronal Ca^  ^ influx via VOCC and its cardioprotective 
anti-exocytotic effect. To summarize, the main findings pertaining to the Gpy 
subunit and the signaling associated with H3R activation were that: (1) H3R 
activation attenuated both peak Ica and DA exocytosis in PCI2 -H3 but not in PC12- 
Hs/p-ARKI cells; (2) A membrane permeable phosducin-like G(3y scavenger 
prevented the anti-exocytotic effect of H3R activation; (3) HsR-induced attenuation 
of cAMP accumulation and DA exocytosis in response to forskolin were the same 
in both PCI2 -H3 and PCI2 -H3/P-ARKI cells.
The data presented herein document whole-cell currents recorded in 
differentiated PCI 2 cells which displayed the typical characteristics of neuronal Ica 
(Bean et al., 1984;Yang and Tsien, 1993) and were responsible for 
neurotransmitter release. The Ica was markedly reduced by the selective H3R 
agonist imetit (Garbarg et al., 1992). This thesis work indicates that the decrease
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in that had previously been described with H3R activation (Silver et al., 
2002;Seyedi et al., 2005), is the result of a reduction in Ca^ "" influx via VOCC. In 
addition, although Goj contribute to the H3R mediated anti-exocytotic effect when 
the adenylyl cyclase-cAMP-PKA pathway is stimulated, a direct Gpy-induced 
inhibition of VOCC, resulting in the attenuation of Ica, plays a pivotal role in the 
H3R-mediated decrease in intracellular Ca^  ^ and its associated anti-exocytotic 
effect.
The Gpy subunit is known to regulate multiple protein targets including 
VOCC (Bonacci et al., 2006) and direct coupling of the subunit to VOCC has 
previously been demonstrated (Herlitze et al., 1996;lkeda, 1996). Previous 
measurements of H3R-mediated effects on VOCC activity neglected to speculate a 
potential role for the Gpy dimer (Takeshita et al., 1998). This work provides 
evidence that GPy subunits liberated from the G-protein trimeric complex following 
the activation of H3R, attenuate Ca^  ^ influx into sympathetic nerve endings and 
consequentially reduce neurotransmitter exocytosis. These signaling events were 
revealed with whole-cell voltage-clamp measurements in PCI2 -H3 cells and 
confirmed the presence of a novel mechanism of H3R transduction, capable of 
attenuating the excessive release of NE from sympathetic nerve endings in 
myocardial ischemia. However, it is noteworthy that GPy subunits liberated 
following H3R activation may also exert an indirect inhibition of Ca^  ^ influx via 
VOCC. This indirect action could be mediated by induction of MAPK activity, 
leading to activation of the EP3R receptor, another Gi/o-coupled receptor with anti- 
exocytotic properties (Levi et al., 2007).
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Chapter 3 of this thesis investigated whether a functional relationship exists 
between sensory C-fibers, cardiac mast cells and sympathetic nerves in 
ischemia/reperfusion. To summarize, the main findings in this section of the thesis 
were that: (1) Chemical stimulation and ischemia /reperfusion increased the 
overflow of CGRP and Substance P from sensory C-fibers into the coronary 
effluent of isolated guinea pig hearts; (2) The increased overflow of neuropeptides 
coincided with increased overflow of renin and NE into the coronary effluent; (3) In 
hearts subjected to ischemia/reperfusion, blockade of CGRP receptors and NK-1 
receptors with specific antagonists attenuated the increased overflow of renin, NE 
and the duration of reperfusion arrhythmias.
The data presented in Chapter 3 of this thesis indicate the presence of an 
important interaction between sensory C-fibers, mast cells and sympathetic nerves 
in myocardial ischemia. The activation of mast cells by CGRP and Substance P is 
already well established (Benyon et al., 1987), as is the proximity of sensory C- 
fibers to mast cells in the heart (Williams et al., 1995). The data presented herein 
are the first to demonstrate that neuropeptides released from sensory C-fibers in 
ischemia/reperfusion activate cardiac mast cells, releasing renin, thereby activating 
a local cardiac RAS. The concept that renin is stored in mast cells is contested by 
some investigators (Danser, 2003;Bader, 2002;Campbell, 2008), despite evidence 
that all the necessary components of a local RAS can be found in the heart (Dostal 
and Baker, 1999;Vane, 2000;Bader et al., 2001 ;Silver et al., 2004). The data 
presented here add support to the concept that renin is present in cardiac mast 
cells and reinforces the important role it plays in the activation of a local cardiac
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RAS and the development of detrimental cardiovascular effects (Mackins et al., 
2006). Moreover, the demonstration that neuropeptides released from sensory C- 
fibers elicit renin release from mast cells adds a further degree of complexity to the 
relationship between sensory and sympathetic innervations of the heart and 
cardiac mast cells in myocardial ischemia.
Activation of TRPV1 on sensory C-fibers with capsaicin elicits the release of 
neuropeptides. In contrast, the release of CGRP and Substance P from sensory C- 
fibers of hearts subjected to ischemia/reperfusion is likely due to the action of 
ROS. It is pertinent to also consider that ROS may themselves activate mast cells 
directly and therefore contribute to local RAS activation. ROS also directly promote 
the release of NE from sympathetic nerves and thus contribute to cardiac 
dysfunction. Mast cells themselves also intrinsically generate ROS (Inoue et al., 
2008) and the release of these radicals may intensify the activation of a local RAS 
in ischemia/reperfusion.
The role played by neuropeptides in cardiac pathophysiology is 
considerably less well defined than that of renin. Some previous studies support a 
beneficial role for peptides released from sensory C-fibers (Kallner and Franco- 
Cereceda, 1998). There are indications that CGRP is key to the beneficial effects 
of ischemic preconditioning (Li et al., 1996;Lu et al., 1996). CGRP is also thought 
to be protective in cardiac anaphylaxis (Dai et al., 2000). Interestingly, a previous 
study had suggested that a cardioprotective effect detected following heat stress 
was due to the release of endogenous CGRP from sensory nerves in the rat (Song 
et al., 1999). These findings appear to contradict the data presented in this thesis.
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Indeed, noxious heat is known to activate TRPV1 (Cesare et al., 1999) and 
therefore would be expected to elicit the release of peptides from sensory C-fibers, 
degranulate mast cells and activate a local cardiac RAS, culminating in cardiac 
dysfunction rather than cardioprotection. This discrepancy may be due to 
differences in animal species and/or experimental protocols. In any event. Chapter 
3 of this thesis clearly demonstrates that a functional link exists between sensory 
C-fibers and cardiac mast cells in ischemia/reperfusion. Substance P and CGRP 
released from sensory nerves elicit the release of renin from mast cells and 
activate a local cardiac RAS, ultimately promoting the release of NE from 
sympathetic nerves.
Since an excessive release of NE in myocardial ischemia is detrimental to 
cardiovascular function, the discovery of a pivotal role for the Gpy subunit in the 
anti-exocytotic effect of H3R is of significant relevance. Similarly, the unveiling of 
an interaction between sensory C-fibers, cardiac mast cells and sympathetic 
nerves in ischemia/reperfusion is of paramount importance because it culminates 
in the activation of a local RAS, promotion of NE release and consequent 
arrhythmic dysfunction. These findings may prove to be crucial in the development 
of new and effective therapeutic strategies in conditions such as myocardial 
ischemia and congestive heart failure.
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5. FUTURE DIRECTIONS
There are several areas of work within this thesis which would benefit from 
additional experiments and concepts that should be subjected to further scrutiny.
Although the PC12 cell line adopts a sympathetic phenotype when exposed 
to NGF, it would be good scientific practice to substantiate the pivotal role of the 
GPy subunit in HsR-mediated effect on VOCC using a primary cell line. An ideal 
model to perform these experiments would be superior cervical ganglion (SCG) 
cells isolated from rat neonates. These cells are truly sympathetic neurons and 
therefore represent a more accurate approximation of cardiac sympathetic nerves. 
Notably, the whole-cell patch clamp technique has been used successfully to 
investigate Ica in SCG cells (Zhu and Ikeda, 1994). SCG cells also presumably 
endogenously express H3R and VOCC and as a result may more accurately reflect 
the composition of sympathetic nerve endings in the heart. The presence of H3R 
should first be confirmed in these cells by Western blot, reverse transcription-PCR 
or immunostaining. It would also be interesting to confirm the role of the Gpy 
subunit in H3R-mediated inhibition of Ca^  ^ influx through VOCC using calcium 
imaging techniques. Calcium imaging has been used previously by members of 
Dr. Roberto Levi’s Lab in collaboration with Dr. Randi Silver to demonstrate that 
H3R activation is linked to a decrease in intracellular Ca^  ^ via VOCC in 
neuroblastoma SH-SY5Y cells transfected with H3R (Silver et al., 2002). Similar 
experiments in the PCI2 -H3 and PCI2 -H3PARK-I cells utilizing imetit and specific 
blockers of VOCC would provide further confirmation of the important role played 
by the GPy subunits in H3R-mediated inhibition of VOCC.
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Immunostaining of guinea pig heart indicating the close proximity of sensory 
C-fibers containing CGRP and Substance P, renin in mast cells and sympathetic 
nerves would support the interaction between these elements and greatly add to 
the impact of this thesis. Our lab and collaborators have experience with the 
immunostaining of renin, in fact this technique was fundamental to the 
demonstration that mast cells are a unique source of renin (Silver et al., 2004). 
Immunostaining of sensory nerves containing CGRP and Substance P in the 
guinea pig heart has previously been attained (Gulbenkian et al., 1987). This study 
also indicated that significant depletion of CGRP and Substance P 
immunoreactivity occurred with capsaicin pretreatment.
The work performed on the functional link between sensory C-fibers, mast 
cells and sympathetic nerves would also benefit from the addition of experiments 
involving the treatment of isolated guinea-pig heart with exogenous CGRP and 
Substance P. Indeed, it would be very interesting to discover if the exogenous 
application of these peptides is associated with increased overflow of renin and 
NE, or the generation of arrhythmias. The presentation of these data may help to 
consolidate the interactions described in this thesis and further illuminate the roles 
played by these neuropeptides in the heart. In addition, the findings in the isolated 
guinea-pig heart should be substantiated in another species to eliminate the 
possibility that the interaction between sensory C-fibers, mast cells and 
sympathetic nerves are species-specific. These experiments would preferably be 
conducted in isolated mouse hearts which have also been shown to harbor mast 
cells containing renin (Mackins et al., 2006). Our lab has considerable experience
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of working with mice hearts and such experiments could be extended to make use 
of H3R knockout mice (Koyama et al., 2003a) and the mast cell-deficient mouse 
(Mackins et al., 2006). Experiments performed on hearts from these mouse lines 
would provide valuable information on the interaction between sensory nerves and 
mast cells and may elucidate the true contribution of H3R and mast cells to this 
relationship. Another useful model of cardiac nerve endings routinely used in our 
lab is the synaptosome model. Since cardiac synaptosomes include the terminals 
of all neuronal types, they should contain both sensory and sympathetic 
components. Therefore, further confirmation of the model proposed in this thesis 
could be achieved if ROS treatment of synaptosomes resulted in the elevated 
release of CGRP, Substance P and NE when compared with control.
The recent demonstration that mast cell renin and local RAS activation 
have a role in bronchoconstriction (Veerappan et al., 2008) is significant in that it 
reveals new therapeutic targets in the treatment of airway disease. It is also 
conceivable that the interaction between sensory nerves and mast cells described 
here in the cardiovascular system may prove to be important in the airway. 
Therefore, it would be fascinating to determine whether a similar relationship exists 
between sensory nerves, mast cells and the activation of a local cardiac RAS in 
the lung. This objective could be achieved by perfusion of the lung in the 
Langendorff apparatus. The lungs would be excised and mounted on a modified 
Langendorff perfusion apparatus and perfused with KH solution (95% oxygen, 5% 
CO2). Lung overflow of p-hexosaminidase, histamine, and renin could then be 
measured in the effluent collected before and after capsaicin treatment. Inasmuch
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as neurokinins are very potent bronchoconstrictors and stimulants of mucus 
bronchial secretion, such an interaction may have significance in asthma, chronic 
obstructive pulmonary disease or neurogenic inflammation of the airway.
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